

## PRODUCT MONOGRAPH

**PrSOMATULINE® AUTOGEL®**

lanreotide injection

60 mg, 90 mg, 120 mg lanreotide (as acetate)/unit (syringe)

Antigrowth hormone, ATC Code: H01C B03

Sponsor: Ipsen Biopharm Limited  
Wrexham, LL13 9UF, UK  
<http://www.ipsen.com/en>

Date of Revision:  
August 31, 2018

Distributed by: Ipsen Biopharmaceuticals Canada Inc.  
5060 Spectrum Way, 5<sup>th</sup> Floor  
Mississauga, Ontario  
L4W 5N5

Submission Control No: 217659

©2018 Ipsen Biopharmaceuticals. All rights reserved.

SOMATULINE is a registered trademark of IPSEN BIOPHARM LTD.

## **Table of Contents**

<b>PART I: HEALTH PROFESSIONAL INFORMATION .....</b>	<b>3</b>
SUMMARY PRODUCT INFORMATION .....	3
INDICATIONS AND CLINICAL USE .....	3
CONTRAINDICATIONS .....	4
WARNINGS AND PRECAUTIONS .....	4
ADVERSE REACTIONS .....	8
DRUG INTERACTIONS .....	16
DOSAGE AND ADMINISTRATION.....	17
OVERDOSAGE.....	19
ACTION AND CLINICAL PHARMACOLOGY.....	19
STORAGE AND STABILITY.....	23
SPECIAL HANDLING INSTRUCTIONS .....	23
DOSAGE FORMS, COMPOSITION AND PACKAGING .....	23
<b>PART II: SCIENTIFIC INFORMATION.....</b>	<b>24</b>
PHARMACEUTICAL INFORMATION .....	24
CLINICAL TRIALS .....	25
DETAILED PHARMACOLOGY .....	32
TOXICOLOGY .....	41
<b>PART III: CONSUMER INFORMATION .....</b>	<b>47</b>

PrSOMATULINE® AUTOGEL®

lanreotide injection  
60 mg 90 mg 120 mg lanreotide (as acetate)/unit (syringe)

PART I: HEALTH PROFESSIONAL INFORMATION

SUMMARY PRODUCT INFORMATION

Route of Administration	Dosage Form / Strength	Clinically Relevant Non medicinal Ingredients
Deep subcutaneous injection	Injection 60 mg, 90 mg, 120 mg per unit (syringe)	None <i>For a complete listing see Dosage Forms, Composition and Packaging section.</i>

INDICATIONS AND CLINICAL USE

SOMATULINE® AUTOGEL® [lanreotide (as acetate)] is indicated for:

- The long-term treatment of patients with acromegaly due to pituitary tumours who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy.
- The relief of symptoms associated with acromegaly.

The goal of treatment in acromegaly is to reduce growth hormone (GH) and age adjusted insulin-like growth factor 1 (IGF-1) levels, and where possible, to achieve normalization of their values.

- The treatment of enteropancreatic neuroendocrine tumours in adult patients with Grade 1 or a subset of Grade 2 (equivalent to Ki67<10%) unresectable, locally advanced or metastatic disease, to delay progression.

The effectiveness of SOMATULINE® AUTOGEL® is based on a phase III placebo-controlled study which demonstrated a benefit in progression-free survival in patients classified with stable disease by RECIST criteria (<20% growth) over 12 to 24 weeks. There was no evidence of an overall survival benefit. Data on hindgut tumours were limited (see **CLINICAL TRIALS**).

- The treatment of adult patients with carcinoid syndrome; when used, SOMATULINE® AUTOGEL® reduces the administration frequency of short-acting somatostatin analog rescue therapy (see **CLINICAL TRIALS**).

### **Geriatrics (> 65 years of age):**

Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in pharmacokinetics (see **WARNINGS AND PRECAUTIONS, Special Populations, Geriatrics**). It is not necessary to alter the starting dose in elderly acromegaly patients (see **DOSAGE AND ADMINISTRATION, Recommended dose and dosage adjustment, Acromegaly**). Clinical studies in patients with enteropancreatic neuroendocrine tumours (NETs) or carcinoid syndrome did not include sufficient numbers of patients aged 65 and over (see **WARNINGS AND PRECAUTIONS, Special Populations, Geriatrics**).

### **Pediatrics (< 18 years of age):**

The safety and effectiveness of SOMATULINE<sup>®</sup> AUTOGEL<sup>®</sup> in pediatric patients have not been established (see **WARNINGS AND PRECAUTIONS, Special Populations, Pediatrics**).

## **CONTRAINDICATIONS**

- Patients who are hypersensitive to this drug (see **WARNINGS AND PRECAUTIONS, Immune**), or to any ingredient in the formulation or component of the container. For a complete listing, see the **DOSAGE FORMS, COMPOSITION AND PACKAGING** section of the product monograph.
- Patients who are hypersensitive to somatostatin or related peptides.
- Patients with complicated, untreated lithiasis of the bile ducts.

## **WARNINGS AND PRECAUTIONS**

### **Serious Warnings and Precautions**

- Loss of blood glucose control (hypoglycemia in diabetic patients; hyperglycemia) can occur (see Endocrine and Metabolism section)
- Gallbladder motility may be reduced and lead to gallstone formation (see Hepatic/Biliary/Pancreatic section)
- Drug interaction with cyclosporine (see **DRUG INTERACTIONS**)

### **Cardiovascular**

Lanreotide may lead to a decrease of heart rate without necessarily reaching the threshold of bradycardia in patients without an underlying cardiac problem. In patients suffering from cardiac disorders prior to lanreotide initiation, sinus bradycardia may occur and therefore heart rate should be monitored (see **Monitoring and Laboratory Tests**).

In 81 patients with baseline heart rates of  $\geq 60$  beats per minute (bpm) treated with SOMATULINE<sup>®</sup> AUTOGEL<sup>®</sup> in enteropancreatic neuroendocrine tumours (NETs) Study 726, the incidence of heart rate  $<60$  bpm was 23% (19/81) as compared to 16% (15/94) of placebo treated patients; ten patients (12%) had documented heart rates  $<60$  bpm on more than one visit. The incidence of documented episodes of heart rate  $<50$  bpm as well as the incidence of bradycardia reported as an adverse event

was 1% in each treatment group. Initiate appropriate medical management in patients who develop symptomatic bradycardia.

### **Driving and Operating Machinery**

Clinical studies in patients with acromegaly, enteropancreatic NETs, or carcinoid syndrome demonstrated that adverse reactions of headache and dizziness were most commonly reported with SOMATULINE<sup>®</sup> AUTOGEL<sup>®</sup> treatment. Patients should be warned to exercise caution when driving or operating machinery while on treatment with SOMATULINE<sup>®</sup> AUTOGEL<sup>®</sup>.

### **Endocrine and Metabolism**

Pharmacological studies in animals and humans show that lanreotide, like somatostatin and its analogues, inhibits the secretion of insulin and glucagon. Hence, patients treated with SOMATULINE<sup>®</sup> AUTOGEL<sup>®</sup> may experience hypoglycemia or hyperglycemia. Blood glucose levels should be monitored when lanreotide treatment is initiated or when the dose is changed and periodically thereafter, and treatment of diabetic patients should be adjusted accordingly (see **Monitoring and Laboratory Tests**). In insulin-dependent patients, insulin requirements may be reduced.

Slight decreases in thyroid function have been seen during treatment with lanreotide in acromegalic patients, though clinical hypothyroidism is rare. Thyroid function tests are recommended where clinically indicated (see **Monitoring and Laboratory Tests**).

### **Gastrointestinal**

The gastrointestinal effects of lanreotide may reduce the intestinal absorption of co-administered drugs.

### **Hepatic/Biliary/Pancreatic**

Lanreotide may reduce gallbladder motility and lead to gallstone formation. Gallbladder ultrasonography is therefore advised at the start of treatment and periodically thereafter (see **Monitoring and Laboratory Tests**).

In hepatic impairment, an increase in Volume of Distribution, Mean Residence Time, AUC, and half-life were observed. Clearance was reduced by 30% in moderate to severe hepatically impaired patients (See **ACTION AND CLINICAL PHARMACOLOGY, Pharmacokinetics, Special Populations and Conditions**).

### ***Acromegaly***

It is recommended that patients with moderate or severe hepatic impairment receive a starting dose of lanreotide (as acetate) of 60 mg (see **DOSAGE AND ADMINISTRATION**).

Patients with moderate or severe hepatic impairment have not been studied for an extended dosing interval of SOMATULINE<sup>®</sup> AUTOGEL<sup>®</sup> 120 mg every 6 or 8 weeks (see **DETAILED PHARMACOLOGY, Pharmacokinetics of SOMATULINE<sup>®</sup> AUTOGEL<sup>®</sup> in Patients with Acromegaly**).

### ***Enteropancreatic NETs***

In patients with enteropancreatic neuroendocrine tumours, SOMATULINE® AUTOGEL® was not studied in patients with mild, moderate, or severe hepatic impairment (as per Child-Pugh score) (see **DOSAGE AND ADMINISTRATION** and **ACTION AND CLINICAL PHARMACOLOGY, Pharmacokinetics, Special Populations and Conditions**).

### ***Carcinoid Syndrome***

In patients with carcinoid syndrome, SOMATULINE® AUTOGEL® was not studied in patients with mild, moderate, or severe hepatic impairment (see **DOSAGE AND ADMINISTRATION** and **ACTION AND CLINICAL PHARMACOLOGY, Pharmacokinetics, Special Populations and Conditions**).

### **Immune**

Allergic reactions (including angioedema and anaphylaxis) have been reported following the administration of SOMATULINE® AUTOGEL® (see **ADVERSE REACTIONS, Post-Market Adverse Drug Reactions**). Use of SOMATULINE® AUTOGEL® is contraindicated in patients with a history of hypersensitivity to lanreotide (see **CONTRAINDICATIONS**).

### **Renal**

#### ***Acromegaly***

Subjects with severe renal impairment show an approximately 2-fold decrease in total serum clearance of lanreotide, with a consequent increase in half-life and AUC (see **ACTION AND CLINICAL PHARMACOLOGY, Pharmacokinetics, Special Populations and Conditions**). It is recommended that patients with moderate or severe renal impairment receive a starting dose of lanreotide of 60 mg (see **DOSAGE AND ADMINISTRATION**).

Patients with moderate or severe renal impairment have not been studied for an extended dosing interval of SOMATULINE® AUTOGEL® 120 mg every 6 or 8 weeks (see **DETAILED PHARMACOLOGY, Pharmacokinetics of SOMATULINE® AUTOGEL® in Patients with Acromegaly**).

### ***Enteropancreatic NETs***

In patients with enteropancreatic neuroendocrine tumours, no effect was observed in total clearance of lanreotide in patients with mild or moderate renal impairment receiving SOMATULINE® AUTOGEL® 120 mg. Patients with severe renal impairment were not studied (see **DOSAGE AND ADMINISTRATION** and **ACTION AND CLINICAL PHARMACOLOGY, Pharmacokinetics, Special Populations and Conditions**).

### ***Carcinoid Syndrome***

In patients with carcinoid syndrome, SOMATULINE® AUTOGEL® was not studied in patients with mild, moderate, or severe renal impairment (see **DOSAGE AND ADMINISTRATION** and **ACTION AND CLINICAL PHARMACOLOGY, Pharmacokinetics, Special Populations and Conditions**).

## **Special Populations**

**Pregnant Women:** There is very limited experience of pregnancy in patients treated with lanreotide, either during clinical trials or from postmarketing reports.

Studies in animals showed a transitory growth retardation of offspring prior to weaning. Although no teratogenic effects have been observed in animals, SOMATULINE® AUTOGEL® should not be administered to pregnant women unless clearly needed.

**Breast-Feeding:** It is unknown if the drug is excreted in human milk. SOMATULINE® AUTOGEL® should not be administered to breast-feeding women.

**Pediatrics (< 18 years of age):** There is no experience of the use of the product in children and therefore the use of SOMATULINE® AUTOGEL® in children cannot be advised.

**Geriatrics (> 65 years of age):** Elderly subjects show an increase in half-life and mean residence time compared to healthy young subjects (see **ACTION AND CLINICAL PHARMACOLOGY, Pharmacokinetics, Special Populations and Conditions**). It is not necessary to alter the starting dose of SOMATULINE® AUTOGEL® in elderly acromegaly patients (see **DOSAGE AND ADMINISTRATION, Recommended dose and dosage adjustment, Acromegaly**). Clinical studies conducted in patients with enteropancreatic neuroendocrine tumours or carcinoid syndrome (see **CLINICAL TRIALS, Enteropancreatic NETs Study 726 and Carcinoid Syndrome Study 730**) did not include sufficient numbers of patients aged 65 and over.

## **Monitoring and Laboratory Tests**

### ***Acromegaly***

Evaluation of GH and IGF-1 levels are useful markers of the disease progression and effectiveness of treatment (see **DOSAGE AND ADMINISTRATION, Recommended dose and dosage adjustment, Acromegaly**).

Slight decreases in thyroid function have been seen during treatment. Thyroid function tests are recommended where clinically indicated.

### ***Acromegaly, Enteropancreatic NETs, and Carcinoid Syndrome***

In patients suffering from cardiac disorders prior to lanreotide initiation, sinus bradycardia may occur and therefore heart rate should be monitored.

The principal pharmacodynamic interaction that may occur is the inhibition of glucagon secretion which may lead to the onset of hypoglycemia in treated diabetic patients, notably insulin-dependent patients. Thus, the insulin requirements in insulin-dependent diabetic patients may be reduced. Patients treated with SOMATULINE® AUTOGEL® may experience hypoglycemia or hyperglycemia. Therefore, blood glucose levels should be monitored when lanreotide treatment is initiated or when the dosage is attuned, and periodically thereafter. The antidiabetic treatment of diabetic patients should be adjusted accordingly.

Lanreotide may reduce gallbladder motility and lead to gallstone formation. Gallbladder ultrasonography is therefore advised at the start of treatment and periodically thereafter.

## ADVERSE REACTIONS

### Adverse Drug Reaction Overview

The adverse reactions commonly reported with lanreotide administration are predominantly local (at injection site) and gastrointestinal.

### Clinical Trial Adverse Drug Reactions

*Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.*

#### *Acromegaly Study 717*

Study 717 was a randomized, double-blind placebo-controlled study, conducted in 108 acromegalic patients treated for one year. Patients received a total of 13 injections at 28 day intervals (one injection of placebo plus 12 injections of SOMATULINE<sup>®</sup> AUTOGEL<sup>®</sup> or 13 injections of SOMATULINE<sup>®</sup> AUTOGEL<sup>®</sup>). The dose could be adapted every 4 injections based on GH or IGF-1 levels.

The total exposure to SOMATULINE<sup>®</sup> AUTOGEL<sup>®</sup> over the three phases of the study is summarized below.

**Table 1: Total exposure to SOMATULINE<sup>®</sup> AUTOGEL<sup>®</sup> during all three phases in Study 717 (Safety Population)**

Statistic	Cumulative lanreotide dose (mg)	Average monthly lanreotide dose (mg) <sup>1</sup>	Duration of active treatment (days) <sup>2</sup>
N	107	107	107
Median	1140.0	98.6	364.0
Mean ± SD	1196.4 ± 301.6	96.4 ± 20.4	348.0 ± 48.7
Minimum, Maximum	270, 1560	58.8, 121.3	86, 400

<sup>1</sup> [Cumulative lanreotide dose/duration of active treatment] x 28

<sup>2</sup> [Date of last lanreotide dose – date of first lanreotide dose] + 28

#### ***Most Commonly Reported Treatment Emergent Adverse Events (TEAEs)***

The incidence of TEAEs for SOMATULINE<sup>®</sup> AUTOGEL<sup>®</sup> 60 mg, 90 mg, and 120 mg compared to placebo as investigated during the first phase of Study 717 are provided in Table 2.



**Table 2: Most commonly ( $\geq 5\%$ ) reported TEAEs during the double-blind phase (1 month = 1 injection) in Study 717 (Safety Population) by dose**

Preferred Term	SOMATULINE <sup>®</sup> AUTOGEL <sup>®</sup>				Placebo (N= 25)	Total (N= 108)*
	60 mg (N= 27)	90 mg (N=27)	120 mg (N= 29)	Overall (N=83)		
	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)
<i>Any adverse event</i>	11 (41)	19 (70)	20 (69)	50 (60)	9 (36)	59 (55)
Diarrhea	3 (11)	10 (37)	13 (45)	26 (31)	0	26 (24)
Abdominal Pain	2 (7)	2 (7)	2 (7)	6 (7)	1 (4)	7 (6)
Bradycardia	3 (11)	2 (7)	2 (7)	7 (8)	0	7 (6)
Weight decrease	2 (7)	4 (15)	1 (3)	7 (8)	0	7 (6)
Anemia	1 (4)	4 (15)	1 (3)	6 (7)	0	6 (6)
Flatulence	0	2 (7)	3 (10)	5 (6)	0	5 (5)

\*Total number of patients included in the safety population for this study phase is 108.

The incidence of the most commonly reported related AEs, i.e. those reported in  $\geq 2\%$  of patients for the SOMATULINE<sup>®</sup> AUTOGEL<sup>®</sup> Study 717 are presented in Table 3 by dose of onset. The majority of AEs observed in this study were mild to moderate in intensity. This table includes all TEAEs which began after the injection of SOMATULINE<sup>®</sup> AUTOGEL<sup>®</sup>, therefore it excludes TEAEs which occurred in patients receiving placebo in the initial double-blind phase. The number of patients included in each dose group is based on the total number of patients who received at least one dose at that dose level; also provided is the total across the three dose groups.

The injections were well tolerated. Injection site reactions, primarily reports of injection site mass and injection site pain, were infrequently reported over the 52-week study occurring in 9% and 9% of patients, respectively.

**Table 3: Treatment Emergent Adverse Events Related to SOMATULINE<sup>®</sup> AUTOGEL<sup>®</sup> Reported in  $\geq 2\%$  of Total Patients on SOMATULINE<sup>®</sup> AUTOGEL<sup>®</sup> in Study 717 (Safety Population) by Dose of Onset**

Adverse Event by Body System	SOMATULINE <sup>®</sup> AUTOGEL <sup>®</sup>			
	60 mg (N = 46)	90 mg (N = 66)	120 mg (N = 74)	Total (N = 107*)
	N (%)	N (%)	N (%)	N (%)
<i>Any AE</i>	23 (50)	33 (50)	51 (69)	72 (67)
<b>Application Site Disorders</b>				
Injection site mass	2 (4)	2 (3)	7 (9)	10 (9)
Injection site pain	3 (7)	3 (5)	4 (5)	10 (9)
Injection site reaction	0 (0)	1 (2)	2 (3)	3 (3)
Injection site bleeding	0 (0)	1 (2)	1 (1)	2 (2)
<b>General Disorders</b>				
Fatigue	1 (2)	4 (6)	3 (4)	8 (7)
Back Pain	2 (4)	0 (0)	1 (1)	3 (3)
Malaise	0 (0)	0 (0)	2 (3)	2 (2)
Chest Pain	0 (0)	0 (0)	2 (3)	2 (2)
<b>Cardiovascular Disorders</b>				
Hypertension aggravated	2 (4)	2 (3)	1 (1)	5 (5)

Heart murmur	0 (0)	0 (0)	2 (3)	2 (2)
<b>Central &amp; Peripheral Nervous System Disorders</b>				
Dizziness	2 (4)	0 (0)	2 (3)	4 (4)
Headache	2 (4)	0 (0)	2 (3)	4 (4)
Vertigo	0 (0)	2 (3)	0 (0)	2 (2)
<b>GI System Disorders</b>				
Diarrhea	10 (22)	19 (29)	34 (46)	50 (47)
Abdominal pain	5 (11)	8 (29)	10 (14)	21 (20)
Flatulence	2 (4)	3 (5)	7 (9)	11 (10)
Nausea	3 (7)	2 (3)	5 (7)	10 (9)
Vomiting	1 (2)	0 (0)	3 (4)	4 (4)
Constipation	1 (2)	1 (2)	2 (3)	4 (4)
Dyspepsia	1 (2)	4 (6)	1 (1)	6 (6)
Anorexia	0 (0)	1 (2)	2 (3)	3 (3)
<b>Heart Rate and Rhythm Disorders</b>				
Bradycardia	7 (15)	5 (8)	3 (4)	14 (13)
<b>Liver and Biliary System Disorders</b>				
Cholelithiasis and/or gallbladder sludge	8 (17)	8 (12)	18 (24)	32 (30)
Gallbladder disorder	3 (7)	3 (5)	2 (3)	8 (7)
Bilirubinemia	1 (2)	1 (2)	0 (0)	2 (2)
Hepatomegaly	0 (0)	1 (2)	1 (1)	2 (2)
<b>Metabolic and Nutritional Disorders</b>				
Hyperglycemia	3 (7)	2 (3)	3 (4)	8 (7)
Weight Decrease	3 (7)	3 (5)	3 (4)	9 (8)
Hypoglycemia	1 (2)	1 (2)	0 (0)	2 (2)
Hypercholesterolemia	2 (4)	1 (2)	0 (0)	2 (2)
Phosphatase Alkaline Increased	0 (0)	1 (2)	1 (1)	2 (2)
<b>Musculo-Skeletal System Disorders</b>				
Arthralgia	1 (2)	5 (8)	1 (1)	6 (6)
Myalgia	1 (2)	1 (2)	1 (1)	3 (3)
Muscle weakness	1 (2)	0 (0)	1 (1)	2 (2)
Skeletal pain	0 (0)	1 (2)	1 (1)	2 (2)
<b>Myo Endo Pericardial &amp; Valve Disorders</b>				
Heart Valve disorders	0 (0)	1 (2)	2 (3)	3 (3)
Aortic stenosis	1 (2)	0 (0)	1 (1)	2 (2)
Aortic valve incompetence	1 (2)	2 (3)	0 (0)	2 (2)
Myocardial infarction	0 (0)	0 (0)	2 (3)	2 (2)
<b>Psychiatric Disorders</b>				
Depression	1 (2)	1 (2)	0 (0)	2 (2)
Nervousness	1 (2)	0 (0)	1 (1)	2 (2)
<b>Red Blood Cell Disorders</b>				
Anemia	2 (4)	2 (3)	2 (3)	6 (6)
<b>Respiratory System Disorders</b>				
Dyspnoea	1 (2)	0 (0)	2 (3)	3 (3)
<b>Skin and Appendages Disorders</b>				
Alopecia	5 (11)	3 (5)	5 (7)	11 (10)
Hair disorder nos	1 (2)	0 (0)	2 (3)	3 (3)
Nail disorder	2 (4)	1 (2)	0 (0)	3 (3)
<b>White Blood Cell and res Disorders</b>				
Leucopenia	0 (0)	0 (0)	2 (3)	2 (2)

\*Total number of patients included in the safety population for these study phases is 107.

**Other related adverse events occurring at an incidence between <2% and ≥1% reported in the pivotal clinical study 717:**

***Application Site Disorders:*** injection site inflammation

***General Disorders:*** asthenia, oedema, pain, sweating increased

***Cardiovascular Disorders:*** cardiomegaly, ECG abnormal

***Central and Peripheral Nervous System Disorders:*** dysaesthesia, gait abnormal, hypoaesthesia, paraesthesia

***Endocrine Disorders:*** hypothyroidism

***Gastrointestinal System Disorders:*** change in bowel habits, gastrointestinal disorder nos, gastroesophageal reflux, haemorrhoids, pancreatitis

***Hearing and Vestibular Disorders:*** tinnitus

***Heart Rate and Rhythm Disorders:*** arrhythmia atrial, arrhythmia ventricular, bundle branch block, heart block

***Liver and Biliary System Disorders:*** cholecystitis, hepatic neoplasm, hepatocellular damage, hepatosplenomegaly

***Metabolic and Nutritional Disorders:*** diabetes mellitus, diabetes mellitus aggravated, vitamin B12 deficiency

***Musculo-Skeletal System Disorders:*** bursitis

***Myo Endo Pericardial & Valve Disorders:*** atrial septal defect, mitral insufficiency

***Neoplasm:*** hepatic neoplasm, neoplasm nos

***Psychiatric Disorders:*** anxiety, appetite increased, impotence, insomnia

***Reproductive Disorders:*** endometrial disorder

***Respiratory System Disorders:*** bronchitis, rhinitis

***Secondary Terms:*** cyst nos

***Urinary System Disorders:*** dysuria, renal pain

***Vascular (Extracardiac) Disorders:*** peripheral ischemia

**Vision Disorders:** cataract, corneal deposits

### **Enteropancreatic NETs Study 726**

Study 726 was a randomized, double-blind placebo-controlled study, conducted in 204 enteropancreatic NETs patients treated for 96 weeks. SOMATULINE® AUTOGEL® 120 mg fixed dose was administered every 4 weeks.

Safety results are based on a median follow-up of approximately 96 weeks in the group treated with SOMATULINE® AUTOGEL® 120 mg and 60 weeks in the group treated with placebo. The rates of discontinuation due to treatment emergent adverse events were 3% in the SOMATULINE® AUTOGEL® arm and 2.9% in the placebo arm.

Table 4 compares the treatment-emergent adverse events reported with an incidence of  $\geq 5\%$  in patients receiving SOMATULINE® AUTOGEL® 120 mg administered every 4 weeks versus placebo. The majority of these events were mild to moderate in severity.

**Table 4: Adverse Reactions Occurring in  $\geq 5\%$  of SOMATULINE® AUTOGEL®-treated Patients with enteropancreatic NETs in Study 726**

<b>Body System Preferred Term</b>	<b>SOMATULINE® AUTOGEL® 120 mg (N = 101) N (%)</b>	<b>PLACEBO (N = 103) N (%)</b>
<b>Any TEAE</b>	<b>89 (88)</b>	<b>93 (90)</b>
<b>Gastrointestinal Disorders</b>	<b>68 (67)</b>	<b>65 (63)</b>
Diarrhoea	35 (35)	36 (35)
Abdominal pain	24 (24)	17 (17)
Vomiting	19 (19)	9 (9)
Nausea	14 (14)	14 (14)
Constipation	12 (12)	13 (13)
Flatulence	12 (12)	9 (9)
Abdominal pain upper	8 (8)	8 (8)
Abdominal discomfort	5 (5)	3 (3)
<b>Infections and Infestations</b>	<b>41 (41)</b>	<b>46 (45)</b>
Nasopharyngitis	9 (9)	16 (16)
Urinary tract infection	9 (9)	9 (9)
<b>General Disorders and Administration Site Disorders</b>	<b>36 (36)</b>	<b>43 (42)</b>
Fatigue	10 (10)	15 (15)
Asthenia	8 (8)	5 (5)
Injection site pain	8 (8)	4 (4)
Oedema peripheral	5 (5)	7 (7)
<b>Musculo-Skeletal and Connective Tissue</b>	<b>34 (34)</b>	<b>24 (23)</b>
Back Pain	12 (12)	11 (11)
Arthralgia	10 (10)	9 (9)
Musculoskeletal pain	7 (7)	3 (3)
Muscle spasms	5 (5)	4 (4)
<b>Nervous System Disorders</b>	<b>32 (32)</b>	<b>19 (18)</b>
Headache	16 (16)	11 (11)
Dizziness	9 (9)	2 (2)

Lethargy	5 (5)	4 (4)
<b>Metabolism and Nutrition Disorders</b>	<b>32 (32)</b>	<b>19 (18)</b>
Decreased appetite	10 (10)	9 (9)
Diabetes mellitus	7 (7)	4 (4)
Hyperglycaemia	6 (6)	0 (0)
Dehydration	5 (5)	1 (1)
<b>Vascular Disorders</b>	<b>24 (24)</b>	<b>18 (18)</b>
Hypertension	13 (13)	5 (5)
<b>Skin and subcutaneous tissue disorders</b>	<b>22 (22)</b>	<b>21 (20)</b>
Pruritus	5 (5)	5 (5)
Alopecia	5 (5)	4 (4)
Rash	5 (5)	3 (3)
<b>Hepatobiliary Disorders</b>	<b>20 (20)</b>	<b>10 (10)</b>
Cholelithiasis	14 (14)	7 (7)
<b>Investigations</b>	<b>18 (18)</b>	<b>14 (14)</b>
Weight decreased	8 (8)	9 (9)
Pancreatic enzymes decreased	6 (6)	0 (0)
<b>Respiratory, Thoracic and Mediastinal Disorders</b>	<b>17 (17)</b>	<b>15 (15)</b>
Dyspnoea	6 (6)	1 (1)
Cough	5 (5)	3 (3)
Oropharyngeal pain	5 (5)	3 (3)
<b>Blood and Lymphatic Disorders</b>	<b>8 (8)</b>	<b>7 (7)</b>
Anemia	6 (6)	1 (1)

TEAE = Treatment-emergent adverse event

Dictionary Name = MedDRA 16.0

A patient is counted only once for each body system and preferred term.

### **Other related adverse events occurring at an incidence between <5% and ≥1% in the clinical study 726:**

**Gastrointestinal disorders:** pancreatic insufficiency, abdominal distension, steatorrhoea, abdominal pain lower, abdominal rigidity, abnormal feces, defecation urgency, dyspepsia, feces pale/discoloured

**General disorders and administrative site conditions:** injection site reactions (induration, granuloma, mass, nodule, pruritus, swelling, rash) pyrexia, chills, influenza-like illness

**Hepatobiliary disorders:** biliary fistula, hepatic failure

**Nervous system disorders:** syncope

**Investigations:** blood glucose decreased, gamma-glutamyltransferase increased

**Metabolism and nutritional disorders:** glucose tolerance impaired

**Psychiatric disorders:** nervousness, depression

**Skin and subcutaneous tissue disorders:** hyperhidrosis, pruritus generalized, skin lesion, dry skin

**Musculoskeletal and connective tissue disorders:** myalgia

**Cardiac disorders:** bradycardia

**Eye disorders:** vision blurred

### ***Carcinoid Syndrome Study 730***

The safety of SOMATULINE® AUTOGEL® 120 mg in patients with histopathologically-confirmed neuroendocrine tumours and a history of carcinoid syndrome (flushing and/or diarrhea) was evaluated in Study 730, a double-blind, placebo controlled trial for 16 weeks, followed by open-label treatment. Patients were randomized to receive SOMATULINE® AUTOGEL® (N=59) or placebo (N=56) administered by deep subcutaneous injection once every 4 weeks. Patients in both arms of Study 730 had access to subcutaneous octreotide as rescue medication for symptom control. Patients were evaluated for safety for up to 5.4 years, with a mean duration of exposure of 2.1 years.

Adverse reactions reported in Study 730 were generally similar to those reported in Study 726 for the enteropancreatic NETs population (see **ADVERSE REACTIONS, Table 4** above). Treatment-emergent adverse events occurring in Study 730 in >5% of SOMATULINE® AUTOGEL®-treated patients and occurring more commonly than in placebo-treated patients (>5% higher incidence) were headache (12% vs. 5%, respectively), dizziness (7% vs. 0%, respectively), and muscle spasm (5% vs. 0%, respectively) by Week 16. Adverse reactions occurring in Study 730 in ≥5% of SOMATULINE® AUTOGEL®-treated patients were nausea (5.2%) vs. placebo (1.8%) by Week 16.

**Adverse reactions occurring at an incidence between <5% and ≥1% in the SOMATULINE® AUTOGEL® arm during the double-blind phase (by Week 16) in the Carcinoid Syndrome clinical study 730:**

***Blood and lymphatic system disorders:*** microcytic anaemia

***Ear and labyrinth disorders:*** deafness permanent

***Gastrointestinal disorders:*** abdominal pain, vomiting, flatulence, constipation, abdominal pain upper, gastritis, feces pale

***General disorders and administrative site conditions:*** fatigue, asthenia, injection site pain

***Investigations:*** weight decreased, blood viscosity increased

***Metabolism and nutritional disorders:*** decreased appetite, hypoglycemia

***Nervous system disorders:*** headache, dizziness, tremor

***Musculoskeletal and connective tissue disorders:*** myalgia

### **Long-term adverse reactions in Study 730:**

The above mentioned adverse reactions occurring by Week 16 persisted and were also reported during the open-label phase of Study 730. Additionally, the adverse reactions reported only during the open-label phase (with a median exposure to SOMATULINE® AUTOGEL® of approximately 20 months) but not during the 16-week double-blind phase in  $\geq 1\%$  of SOMATULINE® AUTOGEL®-treated patients included cholelithiasis (5.9%), abdominal distension (3.0%), hyperglycemia (3.0%), muscle spasms (2.0%), dyspepsia (2.0%), injection site induration (2.0%), and the following adverse reactions reported with an incidence of 1.0% each; diarrhea, oral pain, type 2 diabetes mellitus, neuropathy peripheral, glucose tolerance impaired, impaired fasting glucose, blood glucose increased, blood triglyceride increased, gamma-glutamyl transferase increased, oedema peripheral, visceral pain, nodule, injection site erythema, injection site pruritus, arthralgia, bone pain, conjunctiva hyperaemia, tinnitus, dysmenorrhoea, hot flush, confusional state, hyperhidrosis, and night sweats.

### **Less Common Clinical Trial Adverse Drug Reactions (<1%)**

#### **Acromegaly Study 717**

***Skin and appendages disorders:*** allergic skin reaction

***Gastrointestinal disorders:*** steatorrhea

***Administration site disorders:*** injection site nodule

#### **Enteropancreatic NETs Study 726**

***Skin and appendages disorders:*** allergic skin reaction

**Carcinoid Syndrome Study 730:** none

### **Abnormal Hematologic and Clinical Chemistry Findings**

#### **Acromegaly Study 717**

Slight anemia is not uncommon in acromegaly patients. In the pivotal SOMATULINE® AUTOGEL® study no clinically meaningful changes in hematology or chemistry parameters were noted. Only small mean decreases from baseline to week 52 and LVA were noted for all red cell parameters, including hemoglobin, hematocrit, and red blood cell count. No trends were noted for changes from baseline in red cell or clinical chemistry parameters.

In two additional studies with SOMATULINE® AUTOGEL® there were no clinically significant changes in any hematology or biochemistry parameters over the course of treatment.

#### **Enteropancreatic NETs Study 726**

No clinically meaningful shifts in any of the hematology parameters were observed.

Approximately 23% of patients in the SOMATULINE® AUTOGEL® arm experienced a shift in their HbA1c (%) from normal at baseline to high at the last value compared to 4% of patients in the placebo arm.

### **Carcinoid Syndrome Study 730**

There were no clinically relevant changes in any hematology or biochemistry parameters.

### **Post-Market Adverse Drug Reactions**

Rarely post-injection episodes of malaise with signs of dysautonomia were reported. Rare cases of persisting induration at injection site were reported.

Allergic reactions associated with lanreotide (including angioedema, anaphylaxis, and hypersensitivity) have been reported in the postmarketing environment.

Hepatobiliary disorders including cases of steatorrhea, cholecystitis, and pancreatitis have been reported.

Occurrence of injection site abscesses at the recommended injection site have been reported.

## **DRUG INTERACTIONS**

### **Serious Drug Interactions**

Concomitant administration of lanreotide injection with cyclosporin may decrease blood levels of cyclosporin (see **DRUG-DRUG INTERACTIONS**)

### **Overview**

The gastrointestinal effects of SOMATULINE® AUTOGEL® may reduce the intestinal absorption of co-administered drugs. No significant interaction was found with vitamin K when administered concomitantly with lanreotide.

Interactions with highly plasma bound drugs are unlikely in view of the moderate binding of lanreotide to serum proteins (78% mean serum binding see **DETAILED PHARMACOLOGY, Extrinsic Factor Pharmacokinetic Studies**).

Limited published data indicate that somatostatin analogues might decrease the metabolic clearance of compounds known to be metabolized by cytochrome P450 enzymes, which may be due to the suppression of growth hormone. Since it cannot be excluded that lanreotide may have this effect, other medicinal products mainly metabolized by CYP3A4 and which have a low therapeutic index, (e.g. terfenadine) should therefore be used with caution.

Concomitant administration of bradycardia-inducing drugs (e.g., beta-blockers) may have an additive effect on the reduction of heart rate associated with lanreotide treatment. Dosage adjustments of concomitant drugs may be necessary.

### **Drug-Drug Interactions**

Concomitant administration of lanreotide injection with cyclosporin may decrease blood levels of cyclosporin, hence blood levels of cyclosporin should be monitored.



Concomitant administration of lanreotide and bromocriptine increases the availability of bromocriptine.

*The drugs listed in this section are based on either drug interaction case reports or studies, or potential interactions due to the expected magnitude and seriousness of the interaction (i.e., those identified as contraindicated).*

### **Drug-Food Interactions**

Interactions with food have not been established.

### **Drug-Herb Interactions**

Interactions with herbal products have not been established.

### **Drug-Laboratory Interactions**

Interactions with laboratory tests have not been established.

## **DOSAGE AND ADMINISTRATION**

### **Recommended Dose and Dosage Adjustment**

#### ***Acromegaly***

Patients should begin treatment with SOMATULINE® AUTOGEL® 90 mg given via deep subcutaneous route, at 4 week intervals for 3 months. After 3 months dosage may be adapted as follows:

- GH > 1 to ≤ 2.5 ng/mL, IGF-1 normal and clinical symptoms controlled: Maintain SOMATULINE® AUTOGEL® dosage at 90 mg every 4 weeks
- GH > 2.5 ng/mL, IGF-1 elevated and/or clinical symptoms uncontrolled: Increase SOMATULINE® AUTOGEL® dosage to 120 mg every 4 weeks
- GH ≤ 1 ng/mL, IGF-1 normal and clinical symptoms controlled: Reduce SOMATULINE® AUTOGEL® dosage to 60 mg every 4 weeks

Thereafter, the dose should be adjusted according to the response of the patient as judged by a reduction in symptoms and/or in GH and/or IGF-1 levels.

The starting dose in patients with moderate or severe hepatic or renal impairment should be 60 SOMATULINE® AUTOGEL® via the deep subcutaneous route, at 4 week intervals for 3 months, followed by dose adjustments as described above (see **ACTION AND CLINICAL PHARMACOLOGY, Special Populations and Conditions**).

It is not necessary to alter the starting dose in elderly patients (see **ACTION AND CLINICAL PHARMACOLOGY, Pharmacokinetics, Special Populations and Conditions**).

Patients who are controlled on SOMATULINE® AUTOGEL® 60 mg or 90 mg may be considered for an extended dosing interval of SOMATULINE® AUTOGEL® 120 mg every 6 or 8 weeks. GH and IGF-1 levels should be obtained 6 weeks after this change in dosing regimen to evaluate the persistence of patients' response.

Continued monitoring of patients' response with dose adjustments for biochemical and clinical symptom control is recommended.

Patients with moderate or severe hepatic or renal impairment have not been studied for an extended dosing interval of SOMATULINE® AUTOGEL® 120 mg every 6 or 8 weeks (see **DETAILED PHARMACOLOGY, Pharmacokinetics of SOMATULINE® AUTOGEL® in Patients with Acromegaly**).

### ***Enteropancreatic NETs***

The recommended dose of SOMATULINE® AUTOGEL® is 120 mg administered every 4 weeks by deep subcutaneous injection in the superior external quadrant of the buttock. Treatment with SOMATULINE® AUTOGEL® should be discontinued upon disease progression.

There is no recommended dose adjustment for mild or moderate renal impairment. There is insufficient information to recommend a dose for patients with severe renal impairment or with hepatic impairment of any severity (see **ACTION AND CLINICAL PHARMACOLOGY, Pharmacokinetics, Special Populations and Conditions**).

### ***Carcinoid Syndrome***

The recommended dose of SOMATULINE® AUTOGEL® is 120 mg administered every 4 weeks by deep subcutaneous injection.

If patients are already being treated with SOMATULINE® AUTOGEL® for enteropancreatic NETs, patients should not administer an additional dose for the treatment of carcinoid syndrome.

There is insufficient information to recommend a dose for patients with renal or hepatic impairments of any severity. Specific renal or hepatic impairment studies were not conducted in patients with carcinoid syndrome (see **ACTION AND CLINICAL PHARMACOLOGY, Pharmacokinetics, Special Populations and Conditions**).

### **Missed Dose**

If a dose is missed, the next dose should be administered as soon as possible.

### **Administration**

The injection may be given by a healthcare professional or, for patients considered by their healthcare professional to be on a stable dose of SOMATULINE® AUTOGEL®, by another appropriately trained individual. Alternatively, such patients may self-administer the product after appropriate training. The decision regarding administration by the patient or a trained individual should be taken by the healthcare professional.

SOMATULINE® AUTOGEL® should be injected via the deep subcutaneous route in the superior

external quadrant of the buttock. In the case of self-administration, the injection should be given in the upper outer thigh.

**Regardless of the site of administration, the skin should be stretched prior to injection.** The needle should be inserted rapidly to its full length, perpendicularly to the skin. **The injection site should be alternated between the right and left sides.**

SOMATULINE® AUTOGEL® is provided in a ready-to-use, sterile, pre-filled syringe, fitted with an automatic safety system that automatically locks in place following administration of the product, to help prevent needle stick injury after use. SOMATULINE® AUTOGEL® is for immediate and single use following first opening. No reconstitution is required.

## OVERDOSAGE

If overdose occurs, symptomatic management is indicated. Experience with lanreotide overdose in humans consists of a single case, a 52-year-old acromegalic patient with medical history of diabetes mellitus and hypertension, who had received as a result of drug misuse a 30 mg lanreotide injection daily for 2 months. No acute symptoms or pharmacological signs of overdose were reported. One week after the last injection he experienced a myocardial infarction.

For management of a suspected drug overdose, please contact your local Poison Control Centre.

## ACTION AND CLINICAL PHARMACOLOGY

### Mechanism of Action

Lanreotide is a synthetic octapeptide analogue of natural somatostatin. Somatostatin is an endogenous peptide present in several areas of the central nervous system and in the gastrointestinal tract. It has very powerful inhibitory effects on different cell types.

Like natural somatostatin, lanreotide is a peptide inhibitor of numerous endocrine, neuroendocrine and exocrine mechanisms. It exhibits high affinity for both the somatostatin Type 2 (SSTR2) and Type 5 (SSTR5) receptors that are found in both the pituitary gland and pancreas, as well as in growth hormone, secreting pituitary tumours. Conversely, it has a much lower affinity for somatostatin 1, 3, and 4 receptors. This confers relative specificity of action on growth hormone secretion, making it suitable for the treatment of acromegaly.

**Table 5: Inhibition of Radioligand Binding to Human Recombinant Somatostatin Receptors (K<sub>i</sub>) Comparing Lanreotide and Octreotide (Study RO-10)**

Receptor	Lanreotide (nM) Mean±SEM	Octreotide (nM) Mean±SEM
hSSTR1	2022 ± 394	1154 ± 307
hSSTR2	0.75 ± 0.09	0.53 ± 0.07
hSSTR3	75.2 ± 2.7	40.2 ± 8.1
hSSTR4	1826 ± 264	5029 ± 2001

hSSTR5	5.25 ± 0.80	6.77 ± 0.96
--------	-------------	-------------

There are a number of mechanisms by which somatostatin analogues may inhibit cell proliferation. A direct antitumour effect may result from the activation of somatostatin receptors on tumour cells leading to modulation of intracellular signalling pathways. Somatostatin analogues may also produce an indirect antitumour effect through the inhibition of mitogenic growth factors such as insulin-like growth factor and inhibition of tumour angiogenesis through interaction with somatostatin receptors on endothelial cells and monocytes.

### **Pharmacodynamics**

Primary pharmacology studies using lanreotide showed that lanreotide dose-dependently reduced spontaneous GH secretion in healthy volunteers and acromegalic patients.

Population PK/PD relationship between GH inhibition and lanreotide serum concentration was reported in two analyses including 129 and 107 patients respectively treated with SOMATULINE<sup>®</sup> AUTOGEL<sup>®</sup>. Results from these studies indicated that lanreotide has a maximum capacity of GH inhibition of 82%. Lanreotide concentration providing half of the maximum inhibition of GH (EC50) in responder patients was 0.206 to 0.612 ng/mL and the median lanreotide serum level needed to decrease the GH to 2.5 ng/mL (C2.5) was 0.95 to 1.1 ng/mL. Non-responders do not respond to lanreotide treatment even with high lanreotide concentrations.

An exploratory study in previously untreated patients with large pituitary adenomas suggests that SOMATULINE<sup>®</sup> AUTOGEL<sup>®</sup> induces pituitary tumour volume reduction.

The potential for formation of lanreotide antibodies has been examined during the conduct of efficacy studies using lanreotide. Laboratory investigations showed that non-specific binding (NSB) >10% was present in a small minority of patients treated with lanreotide, and in a few patients the binding was specific for lanreotide and associated with serum antibodies.

Somatostatin was not bound by any of the specimens tested. The safety profiles of patients with NSB values <10%, between 10 and 30% and >30% were similar and there was no evidence that any of the serious adverse events that were reported were due to hypersensitivity reactions. Clinical investigations failed to demonstrate any differences in response to lanreotide treatment between patients with NSB >10% or NSB >25% versus patients who did not exhibit NSB at these levels.

The majority of patients with elevated levels of plasma chromogranin A and/or urinary 5-HIAA (5-hydroxyindoleacetic acid) who received treatment with SOMATULINE<sup>®</sup> AUTOGEL<sup>®</sup> had a decrease in the levels of these tumour markers.

## Pharmacokinetics

### *Pharmacokinetics of SOMATULINE® AUTOGEL® in Healthy Volunteers*

**Table 6a: Summary of Lanreotide's Pharmacokinetic Parameters in Healthy Volunteers After a Single Dose of SOMATULINE® AUTOGEL® 60, 90, and 120mg**

Parameter	60 mg		90 mg		120 mg	
	Mean	SD	Mean	SD	Mean	SD
C <sub>max</sub> (ng/mL)	4.246	1.934	8.391	4.915	6.785	3.641
AUC <sub>∞</sub> (ng/mL/h)	1904.98	564.09	2984.35	1214.04	3552.26	947.33
t <sub>max</sub> (h)*	8 (4 to 336)	---	12 (4 to 336)	---	7 (2 to 48)	--
t <sub>½</sub> (h)	664	455	860	431	816	334
t <sub>lag</sub> (h)	<1.0	0.0	<1.0	0.0	<1.0	0.0
F (%)	83.25	34.56	78.14	25.87	80.87	24.18

\* = Median (range) value

### *Pharmacokinetics of SOMATULINE® AUTOGEL® in Patients with Acromegaly*

**Table 6b: Summary of Lanreotide's Pharmacokinetic Parameters in Acromegalic Patients After Four Doses of SOMATULINE® AUTOGEL® 60, 90, and 120mg**

Parameter	60 mg		90 mg		120 mg	
	Mean	SD	Mean	SD	Mean	SD
C <sub>max,ss</sub> (ng/mL)	3.821	0.509	5.694	1.672	7.685	2.470
AUC <sub>τ</sub> (ng·h/mL)	1650.96	204.72	2042.64	410.40	3039.84	663.84
T <sub>max,ss</sub> (d)*	84.62	(84.17-85.99)	84.29	(84.17 – 85.99)	84.66	(84.33 – 85.97)
C <sub>min,ss</sub> (ng/mL)	1.822	0.304	2.511	0.882	3.762	1.012
C <sub>avg</sub> (ng/mL)	2.457	0.305	3.040	0.611	4.523	0.988
PTF (%)	81	--	108	--	86	--

\* = Median (range) value

PTF = Peak Trough Fluctuation

**Distribution:** Studies with lanreotide after intravenous administration at doses of 7, 21, and 42 µg/kg have demonstrated that it shows limited extravascular distribution, with a mean V<sub>ss</sub> of 0.186 to 0.194 L/kg.

Lanreotide human serum proteins binding studies were performed *in vitro* obtaining a range of values from 79 to 83% at lanreotide concentrations between 12 and 60 ng/ml.

**Metabolism:** Lanreotide is metabolised extensively in the gastrointestinal tract after biliary excretion.

The values of apparent elimination half-life of SOMATULINE® AUTOGEL® after deep s.c. administration range from 28 to 36 days.

**Excretion:** After a single s.c. dose of 3 mg of lanreotide, less than 1% of the administered dose was recovered in urine and renal clearance was <1% of total plasma clearance. After s.c. infusion of

lanreotide, the fraction of lanreotide excreted in the urine at steady state was 1% to 5% for a dose of 0.75 mg/day.

Data for fecal excretion showed that less than 0.5% of the administered dose was recovered over a 24-hour period at steady state. Therefore, urinary and fecal excretion of unchanged lanreotide represents only a small fraction of the total dose administered.

No gender differences were found in PK parameters.

#### ***Pharmacokinetics of SOMATULINE® AUTOGEL® in Patients with enteropancreatic NETs***

In a population PK analysis in 290 NETs patients receiving SOMATULINE® AUTOGEL®, rapid initial release of lanreotide was seen with mean  $C_{max}$  values of  $7.49 \pm 7.58$  ng/mL reached within the first day after a single injection. Steady-state concentrations were reached after 4 to 5 injections of SOMATULINE® AUTOGEL® 120 mg every 4 weeks and were sustained up to the last assessment (up to 96 weeks after the first injection). At steady state, the mean  $C_{max}$  values were  $13.9 \pm 7.44$  ng/mL and the mean trough serum levels were  $6.56 \pm 1.99$  ng/mL. The mean apparent terminal half-life was  $49.8 \pm 28.0$  days.

#### **Special Populations and Conditions**

**Pediatrics:** No studies in pediatrics were performed.

**Geriatrics:** With the immediate-release formulation, healthy elderly subjects showed an 85% increase in half-life and a 65% increase in mean residence time of lanreotide compared to healthy young volunteers. However, there was no change in either AUC or  $C_{max}$  of lanreotide in elderly subjects compared to healthy young subjects (see **DETAILED PHARMACOLOGY, Pharmacokinetics of SOMATULINE® AUTOGEL® in Healthy Volunteers**). It is not necessary to alter the starting dose in elderly acromegaly patients.

In a population PK analysis of enteropancreatic NETs patients treated with SOMATULINE® AUTOGEL®, including 122 patients aged 65 to 85 years, no effect of age on clearance and volume of distribution of lanreotide was observed.

**Hepatic Insufficiency:** In patients with hepatic impairment, an increase in volume of distribution, mean residence time, AUC and half-life were observed with the lanreotide immediate-release formulation. Clearance was reduced by 30% in patients with moderate to severe hepatic impairment, suggesting that clearance of lanreotide does not only depend on hepatic function (see **DETAILED PHARMACOLOGY, Intrinsic Factor Pharmacokinetic Studies**). Acromegaly patients with moderate to severe hepatic impairment should begin treatment with SOMATULINE® AUTOGEL® 60 mg.

Patients with moderate to severe hepatic impairment have not been studied for an extended dosing interval of SOMATULINE® AUTOGEL® 120 mg every 6 or 8 weeks (see **DETAILED PHARMACOLOGY, Pharmacokinetics of SOMATULINE® AUTOGEL® in Patients with Acromegaly**). No enteropancreatic NETs or carcinoid syndrome patients with hepatic impairment (as per Child-Pugh score) were studied.

**Renal Insufficiency:** Lanreotide immediate-release formulation has been studied in patients with end-stage renal function on dialysis, but has not been studied in patients with mild or moderate renal impairment. In subjects with severe renal impairment, total serum clearance of lanreotide is decreased by approximately two-fold, with a consequent two-fold increase in half-life and AUC (see **DETAILED PHARMACOLOGY, Intrinsic Factor Pharmacokinetic Studies**). Acromegaly patients with moderate to severe renal impairment should begin treatment with SOMATULINE<sup>®</sup> AUTOGEL<sup>®</sup> 60 mg.

Acromegaly patients with moderate or severe renal impairment have not been studied for an extended dosing interval of SOMATULINE<sup>®</sup> AUTOGEL<sup>®</sup> 120 mg every 6 or 8 weeks (see **DETAILED PHARMACOLOGY, Pharmacokinetics of SOMATULINE<sup>®</sup> AUTOGEL<sup>®</sup> in Patients with Acromegaly**).

No effect on clearance of lanreotide was observed in a population PK analysis of enteropancreatic NETs patients, including 165 patients with mild or moderate renal impairment (106 and 59, respectively) treated with SOMATULINE<sup>®</sup> AUTOGEL<sup>®</sup>. Enteropancreatic NETs patients with severe renal impairment were not studied.

In patients with carcinoid syndrome, SOMATULINE<sup>®</sup> AUTOGEL<sup>®</sup> was not studied in patients with mild, moderate, or severe renal impairment.

#### **STORAGE AND STABILITY**

Store under refrigeration (+2 to +8°C) in its original package.

#### **SPECIAL HANDLING INSTRUCTIONS**

Not applicable.

#### **DOSAGE FORMS, COMPOSITION AND PACKAGING**

SOMATULINE<sup>®</sup> AUTOGEL<sup>®</sup> is supplied in a polypropylene, sterile, pre-filled syringe with an automatic needle protection system and fitted with a stainless steel needle.

Each pre-filled syringe is packed in a polyethylene terephthalate/aluminium/polyethylene laminated pouch.

Box of one individual 60 mg dose in a 0.5 mL syringe with a needle (1.2 mm X 20 mm).

Box of one individual 90 mg dose in a 0.5 mL syringe with a needle (1.2 mm X 20 mm).

Box of one individual 120 mg dose in a 0.5 mL syringe with a needle (1.2 mm X 20 mm).

SOMATULINE<sup>®</sup> AUTOGEL<sup>®</sup> is an extended release preparation intended for deep subcutaneous injection. The only excipients are water for injection and glacial acetic acid (for pH adjustment).

## PART II: SCIENTIFIC INFORMATION

### PHARMACEUTICAL INFORMATION

#### Drug Substance


Common name: Lanreotide acetate (USAN)

Chemical name: [cyclo S-S]-3-(2-naphthyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-L-threoninamide, acetate


Molecular formula:  $C_{54}H_{69}N_{11}O_{10}S_2 (CH_3COOH)_x$   
Where  $x = 1.0$  to  $2.0$

Molecular mass: 1096.34 g/mol (base)

Structural formula:



or



$x (CH_3COOH)$   
where  $x = 1.0$  to  $2.0$

Physicochemical properties:

Appearance: White to off-white amorphous powder.

Solubility: The solubility of lanreotide in aqueous solution varies little with pH, except at extreme pH values, most notably at alkaline pH.



## CLINICAL TRIALS

### *Acromegaly Study 717*

The clinical efficacy of SOMATULINE<sup>®</sup> AUTOGEL<sup>®</sup> was assessed in one pivotal clinical trial (E-28-52030-717). The study was a randomized, double blind, placebo-controlled study, conducted in 108 acromegalic patients treated for one year. Half (50%) of the patients had never been treated with a somatostatin analog or dopamine agonist, or had stopped treatment for acromegaly three or more months prior to their participation in the study. For inclusion into study 717, these patients were required to have a mean GH level >5 ng/mL at their first visit. The other 50% of the patients had received treatment with a somatostatin analog or a dopamine agonist prior to study entry (requiring an appropriate wash-out of this therapy before receiving the first injection of SOMATULINE<sup>®</sup> AUTOGEL<sup>®</sup>).

The median age of patients enrolled was 54.0 years with a range of 19-84 years. A similar number of males (n=51) and females (n=57) were treated and the median duration from diagnosis of acromegaly was approximately 3 years.

Upon entry, patients were randomly allocated to receive a deep s.c. injection of SOMATULINE<sup>®</sup> AUTOGEL<sup>®</sup> 60 mg, 90 mg, or 120 mg or placebo (3:1). After the initial placebo controlled phase, patients entered a fixed-dose phase where they received injections of SOMATULINE<sup>®</sup> AUTOGEL<sup>®</sup> at 4 week intervals for 4 injections, followed by a dose-titration phase of 8 injections (a total of 13 injections; including placebo phase). During the titration phase the dose could be adapted after 3 months according to the patients' individual GH and IGF 1 levels.

## Study Results

**Table 7: Results of Study 717 in specific indication**

<b>Primary Endpoints</b>	<b>Associated value and statistical significance (comparison SOMATULINE<sup>®</sup> AUTOGEL<sup>®</sup> versus placebo) n/N - % p value</b>
The proportion of patients with a >50% decrease in mean GH from baseline 4 weeks after a single injection, comparing each AUTOGEL <sup>®</sup> group (60, 90, and 120 mg) versus placebo. The combined SOMATULINE <sup>®</sup> AUTOGEL <sup>®</sup> group was also compared to placebo.	Placebo: 0/25 – 0%  AUTOGEL <sup>®</sup> 60 mg: 14/27 – 52%; p <0.001 AUTOGEL <sup>®</sup> 90 mg: 12/27 – 44%; p<0.001 AUTOGEL <sup>®</sup> 120 mg: 26/29 – 90%; p<0.001 AUTOGEL <sup>®</sup> Combined: 52/83 – 63%; p<0.001
<b>Secondary Endpoints</b>	<b>SOMATULINE<sup>®</sup> AUTOGEL<sup>®</sup> (all combined doses) n/N - %</b>
The proportion of patients with a >50% decrease in mean GH from baseline at weeks 16, 32, 52 and Last Value Available post-baseline (LVA).	Wk 16: 77/105 – 73% Wk 32: 82/103 – 80% Wk 52: 80/98 – 82% LVA: 82/107 – 77%
The proportion of patients with mean GH ≤2.5 ng/mL over time	Wk 16: 52/105 – 50% Wk 32: 59/103 – 57% Wk 52: 53/98 – 54% LVA: 55/107 – 51%
The proportion of patients with normalized IGF-I over time	Wk 16: 58/105 – 55% Wk 32: 57/103 – 55% Wk 52: 58/98 – 59% LVA: 61/107 – 57%
The proportion of patients with mean GH ≤2.5 ng/mL and normalized IGF-I over time	Wk 16: 41/105 – 39% Wk 32: 46/103 – 45% Wk 52: 42/98 – 43% LVA: 43/106 – 41%
<b>Symptoms</b>	<b>SOMATULINE<sup>®</sup> AUTOGEL<sup>®</sup> (all combined doses)</b>
	By the end of the study, the acromegaly symptoms of headache, perspiration, fatigue, swelling of extremities, and joint pain had improved from baseline or were stable in 88% to 94% of patients.

## Enteropancreatic NETs Study 726

A Phase 3, 96-week, fixed-duration, randomized, double-blind, multicenter, placebo-controlled trial of SOMATULINE® AUTOGEL® was conducted in patients with enteropancreatic neuroendocrine tumours to assess the antiproliferative effect of lanreotide.

Patients had non-functioning metastatic and/or locally advanced inoperable disease with histologically confirmed Grade 1 or a subset of Grade 2 (equivalent to Ki67 <10%) tumours, originating in the pancreas, midgut, hindgut, or of unknown primary location.

Randomization was stratified by previous therapy at entry and the presence/absence of progression at baseline as assessed by Response Evaluation Criteria in Solid Tumours (RECIST 1.0) during a 3- to 6-month screening phase. Approximately 96% of patients had stable disease at baseline.

The primary endpoint was progression-free survival (PFS) measured as time to either disease progression by RECIST 1.0 or death within 96 weeks after first treatment administration, as assessed by a central, independent, radiological review.

Patients were randomized 1:1 to receive either SOMATULINE® AUTOGEL® 120 mg every 4 weeks (n=101) or placebo (n=103). Baseline patient and disease characteristics are summarized in Table 8.

**Table 8: Summary of Baseline Patient and Disease Characteristics in the Phase 3 Trial of Patients with enteropancreatic NETs**

	SOMATULINE® AUTOGEL® 120 mg (N=101)	Placebo (N=103)
<b>Age (years)</b> Mean (range)	63.3 (30 to 83)	62.2 (31 to 92)
<b>Sex, n (%)</b> Male Female	53 (52.5) 48 (47.5)	54 (52.4) 49 (47.6)
<b>Race, n (%)</b> Asian Black/African American Caucasian/White	2 (2.0) 2 (2.0) 97 (96.0)	5 (4.9) 2 (1.9) 96 (93.2)
<b>Primary tumour location, n (%)</b> Pancreas Midgut Hindgut Other/Unknown	42 (41.6) 33 (32.7) 11 (10.9) 15 (14.9)	49 (47.6) 40 (38.8) 3 (2.9) 11 (10.7)
<b>Proliferation Index Ki67%, n (%)</b> ≤2% >2% to <10% Unknown <sup>a</sup>	52 (51.5) 31 (30.7) 18 (17.8)	51 (49.5) 29 (28.1) 23 (22.3)
<b>Grade of tumour<sup>b</sup>, n (%)</b> G1 G2 Missing	69 (68.3) 32 (31.7) 0	72 (69.9) 29 (28.2) 2 (1.9)
<b>Hepatic tumour load, n (%)</b> 0% to ≤10%	49 (48.5)	58 (56.3)

>10% to ≤25%	13 (12.9)	17 (16.5)
>25% to <50%	39 (38.6)	28 (27.2)
<b>Previous chemotherapy for NET, n (%)</b>		
Yes	14 (13.9)	15 (14.6)
No	86 (86.1)	88 (85.4)
<b>Previous surgery of the primary tumour, n (%)</b>		
Yes	40 (39.6)	39 (37.9)
No	61 (60.4)	64 (62.1)
<b>Baseline CgA, n (%)</b>		
≤ULN	33 (32.7)	34 (33.0)
>1 to >2 ULN	66 (65.4)	66 (64.1)
Missing	2 (2.0)	3 (2.9)
<b>Progression at baseline, n (%)</b>		
Yes	4 (4.0)	5 (4.9)
No	97 (96.0)	98 (95.1)

N= total number of subjects in group; n=number of subjects with assessment

G1=Grade 1; G2=Grade 2; ULN= upper limit of normal; CgA= Chromogranin A

<sup>a</sup>The Ki67 is <10%, but the Ki67 could not be reliably quantified (these subjects were enrolled based on the mitotic index, which was ≤2 mitoses/10 HPF)

<sup>b</sup>G1=Mitotic count <2 mitoses/10 HPF and/or Ki67 ≤2%; G2= Mitotic count 2-20 mitoses/10 HPF and/or Ki67 >2% to 20%


Monthly treatment with SOMATULINE<sup>®</sup> AUTOGEL<sup>®</sup> demonstrated a statistically significant improvement in PFS, resulting in a 53% reduction in tumour progression or death when compared to placebo (p=0.0002). The median PFS for SOMATULINE<sup>®</sup> AUTOGEL<sup>®</sup> was not reached at 96 weeks while the median PFS for placebo was 72 weeks, as shown in Table 9 and Figure 1.

**Table 9: Efficacy Results of the Phase 3 Study**

	Median Progression-free survival (weeks)		Hazard Ratio (95% CI)	Reduction in risk of progression or death	p-value
	SOMATULINE <sup>®</sup> AUTOGEL <sup>®</sup> (n=101)	Placebo (n=103)			
All patients	>96 weeks	72.0 weeks (95% CI: 48.6, 96.0)	0.47 (0.30, 0.73)	53%	0.0002
Primary Tumour Type					
Pancreas	(n=42)	(n=49)			
	>96 weeks	48.6 weeks (95% CI: 37.7, 73.1)	0.58 (0.32, 1.04)	42%	0.0637
Midgut	(n=33)	(n=40)			
	>96 weeks	84.6 weeks (95% CI: 68.1, NC)	0.35 (0.16, 0.80)	65%	0.0091
Hindgut	(n=11)	(n=3)			
	>96 weeks	97.7 weeks (95% CI: 48.1, 97.7)	1.46 (0.16, 13.24)	--	0.7114
Unknown/other	(n=15)	(n=11)			
	>96 weeks	60.0 weeks (95% CI: 25.1, NC)	0.20 (0.04, 1.03)	80%	0.0341


NC= not calculable

**Figure 1: Kaplan-Meier Progression-Free Survival Curves**



The beneficial effect of SOMATULINE<sup>®</sup> AUTOGEL<sup>®</sup> in reducing the risk of progression or death was consistent, regardless of the location of primary tumour, hepatic tumour load, previous chemotherapy, baseline Ki67, tumour grade, age and of other pre-specified characteristics as shown in Figure 2.

**Figure 2: Results of Subgroup analyses of PFS based on separate Cox Proportional Hazards models**



Note: median value of BMI is 26.2 kg/m<sup>2</sup>

### ***Carcinoid Syndrome Study 730***

Study 730 was a multicenter, randomized, 16-week, double-blind, placebo-controlled trial of 115 patients with histopathologically-confirmed neuroendocrine tumours and a history of carcinoid syndrome (flushing and/or diarrhea). The study duration for efficacy was 52 weeks (4 weeks baseline screening, 16 weeks double-blind treatment, and 32 weeks open-label treatment), followed by an extended open-label safety phase.

Patients were randomized 1:1 to receive SOMATULINE® AUTOGEL® 120 mg (n=59) or placebo (n=56) by deep subcutaneous injection every 4 weeks. Patients were instructed to self-administer a short acting somatostatin analog (SSA) (subcutaneous octreotide ≤600µg per day) as rescue medication, as needed, for symptom control. The use of short-acting octreotide and the severity and frequency of diarrhea and flushing symptoms were reported daily in electronic patient diaries. The primary efficacy outcome measure was the percentage of days in which patients received at least one injection of rescue medication for symptom control during the 16-week double-blind phase. Average daily frequencies of diarrhea and flushing events were assessed secondarily.

The patient population had a mean age of 58.6 years (range 27-85 years), 58% were female and 77% were Caucasian. The study included patients who had been previously treated with a SSA, as well as patients who were SSA-naïve. Fifty six percent of patients had received SSA therapy (octreotide) prior to randomization (see **Table 10**), and 84% of patients experienced moderate or severe diarrhea or flushing at baseline.

**Table 10: Baseline Clinical and Demographic Characteristics in Study 730**

	Somatuline Autogel 120 mg (N=59)	Placebo (N=56)
<b>Age (years)</b>		
Mean	57.9	59.3
<b>Sex, n (%)</b>		
Male	27 (45.8)	21 (37.6)
Female	32 (54.2)	35 (62.5)
<b>Race, n (%)</b>		
White	44 (74.6)	44 (78.6)
Multiracial	7 (11.9)	6 (10.7)
Asian	6 (10.2)	3 (5.4)
Black/African American	2 (3.4)	3 (5.4)
<b>Time from first symptom to study treatment initiation, n (%)</b>		
<1 year	14 (23.7)	18 (32.1)
≥1 year	45 (76.3)	38 (67.9)
<b>Time from diagnosis to study treatment initiation, n (%)</b>		
<1 year	19 (32.2)	22 (39.3)
≥1 year	40 (67.8)	34 (60.7)
<b>Region and prior SSA therapy, n (%)</b>		
United States	21 (35.6)	19 (33.9)
Prior SSA therapy	19 (32.2)	17 (30.4)
SSA-naïve	2 (3.4)	2 (3.6)
Non-United States	38 (64.4)	37 (66.1)
Prior SSA therapy	14 (23.7)	14 (25)
SSA-naïve	24 (40.7)	23 (41.1)
<b>Prior SSA therapy ≤3 months before screening, n (%)</b>		
Yes	28 (47.5)	28 (50)
No	31 (52.5)	28 (50)

<b>Prior use of short-acting octreotide, n (%)</b>		
Yes	15 (25.4)	9 (16.1)
No	44 (74.6)	47 (83.9)
<b>Use of short-acting octreotide during screening, n (%)</b>		
Yes	30 (50.8)	29 (51.8)
No	29 (49.2)	27 (48.2)

Patients in the SOMATULINE® AUTOGEL® arm had 15% fewer days on rescue medication compared to patients in the placebo arm (33.7% vs 48.5% of days, respectively; p=0.0165). The beneficial effect of SOMATULINE® AUTOGEL® in reducing rescue medication use was evident regardless of baseline characteristics, including prior SSA use, duration of prior SSA use, and global region.

The average daily frequencies of diarrhea and flushing events in patients treated with SOMATULINE® AUTOGEL® (and rescue medication) were numerically lower compared to patients treated with placebo (and rescue medication), but were not statistically significantly different by hierarchical statistical testing.

## **DETAILED PHARMACOLOGY**

### **Clinical Pharmacodynamics**

The dose and concentration of SOMATULINE® AUTOGEL® was chosen with the help of results from an analysis of the relationship between lanreotide serum levels and GH plasma levels. This analysis was conducted using data from five clinical trials in which lanreotide was administered over a range of doses, routes and durations. The main finding from this analysis was that the concentration of lanreotide required to decrease the GH levels to 2.5 ng/mL was between 2 ng/mL and 3.5 ng/mL (60% to 81% of patients showed GH normalization at these concentrations). Non-responders do not respond to lanreotide treatment even with high lanreotide concentrations.

In Study 730, patients with carcinoid syndrome treated with SOMATULINE® AUTOGEL® 120 mg every 4 weeks showed greater reduction from baseline to Week 12 in mean levels of urinary 5-hydroxyindole acetic acid (5-HIAA) compared with placebo.

### ***Secondary pharmacological effects***

The secondary pharmacological effects of lanreotide are those observed with somatostatin analogs. Somatostatin is widely distributed in cells throughout the bodies of vertebrates and has pleiotropic actions. Therefore, the effects of lanreotide on several physiological systems that are regulated by somatostatin such as inhibition of insulin, glucagons and somatostatin have been investigated.

Lanreotide provoked a physiological picture of slight glucose intolerance, characterized by



decreased plasma levels of insulin and C-peptide and increased plasma levels of glucose. This effect was dose-related and attenuated over seven days of dosing. A study in patients with Type I or Type II diabetes mellitus evaluated the effects of a continuous, 21-day infusion of lanreotide. Lanreotide appeared to reduce the insulin requirements in patients with diabetes mellitus and had only a transient effect on blood glucose levels.

Five studies have been conducted to investigate the effects of lanreotide on digestive hormone secretions in healthy subjects. Similarly, to somatostatin, lanreotide significantly reduced PP, motilin, and GIP levels (AUC values) and post prandial gastrin secretion, but did not affect secretin.

Somatostatin inhibits bile secretion and pancreatic secretion of bicarbonate and enzymes. Similarly, lanreotide inhibited the volume of exogenously stimulated (secretin and CCK) pancreatic secretion and pancreatic bicarbonate and amylase secretion only on Day 2 after administration. Lanreotide did not significantly affect exogenously stimulated biliary secretion of bilirubin. Meal-stimulated secretion of amylase and bilirubin (AUC values) were significantly inhibited by lanreotide only on Day 2.

Somatostatin inhibits gastric acid secretion by inhibiting gastrin and by direct action on parietal cells. Lanreotide dose-dependently increased median gastric pH values and increased the duration of decreased acidity when given as a 24-hour infusion.

The human digestive tract and pancreas contain a large number of cells that secrete somatostatin. Somatostatin inhibits intestinal secretion of calcium, glucose, galactose, glycerol, fructose, xylose, lactose, amino acids, triglycerides and water.

When studied, as expected, lanreotide significantly reduced PGE1 stimulated jejunal secretions of water, sodium, potassium, and chloride.

Somatostatin reduces blood flow to the small intestine. It inhibits mesenteric blood flow and restricts portal flow by constricting splanchnic blood vessels. Some studies have shown that GH and IGF-1 increase glomerular filtration rate (GFR) and renal plasma flow in healthy volunteers, and the somatostatin analogue octreotide decreased GFR in insulin-dependent diabetics and acromegalics. Three studies investigated the effects of lanreotide on renal and splanchnic blood flow in healthy subjects.

These studies showed that lanreotide decreases SMA and portal venous flow but has no effect on renal blood flow.

Inhibition of gallbladder contractility is a known effect of the drug class. The somatostatin analogue octreotide inhibits gallbladder contractility and facilitates formation of gallstones; approximately 18% of patients treated chronically develop either gallbladder sludge or stones.

As expected, a single injection of lanreotide also significantly inhibited basal and post-prandial gallbladder contraction. Somatostatin inhibits the release of thyroid-releasing hormone (TRH) in humans. This effect is readily observed in patients who are hypothyroid or who undergo stimulation with TRH. The three studies which investigated the effects of lanreotide on thyroid parameters confirmed that lanreotide administered as continuing infusion significantly inhibited nocturnal TSH in healthy volunteers and when administered repeatedly slightly affected TSH values compared to baseline in acromegalic patients. Somatostatin inhibits prolactin secretion. In cultured prolactinomas, this inhibition appeared to be mediated by the somatostatin receptor (SSTR) 5 receptor, but not the SSTR2 receptor. Prolactinomas appear to express only SSTR1 and SSTR5, and SSTR5 expression is correlated with prolactin regulation. Prolactin levels were measured in two studies conducted with lanreotide. In both of these studies, lanreotide treatment reduced prolactin levels.

Although acute administration of somatostatin strongly inhibits exocrine pancreatic secretions, divergent results have been published after prolonged treatment. Evidence from studies with the SST analogue octreotide suggests that the degree of inhibition of pancreatic secretion may decrease with continuing treatment. Inhibition of pancreatic enzyme secretion persisted after six days of treatment with the somatostatin analogue octreotide, but the degree of inhibition subsided from 80% to about 60% of control values, indicating an escape from the inhibitory effect of octreotide on CCK-stimulated enzyme secretion. A similar trend has been seen with acute and chronic administration of lanreotide.

Laboratory investigations of acromegalic patients treated with SOMATULINE<sup>®</sup> AUTOGEL<sup>®</sup> in clinical studies show that the percentage of patients with putative antibodies at any time point after treatment is low (<1% to 4% of patients in specific studies whose antibodies were tested). The antibodies did not appear to affect the efficacy or safety of SOMATULINE<sup>®</sup> AUTOGEL<sup>®</sup>.

In Study 726, development of anti-lanreotide antibodies was assessed using a radioimmunoprecipitation assay. In patients with enteropancreatic NETs receiving SOMATULINE<sup>®</sup> AUTOGEL<sup>®</sup>, the incidence of anti-lanreotide antibodies was 3.7% (3 of 82) at 24 weeks, 10.4% (7 of 67) at 48 weeks, 10.5% (6 of 57) at 72 weeks, and 9.5% (8 of 84) at 96 weeks. Assessment for neutralizing antibodies was not conducted. In Study 730, less than 2% (2 of 108) of carcinoid syndrome patients treated with SOMATULINE<sup>®</sup> AUTOGEL<sup>®</sup> developed anti-lanreotide antibodies.

The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to SOMATULINE<sup>®</sup> AUTOGEL<sup>®</sup> with the incidence of antibodies to other products may be misleading.


## Clinical Pharmacokinetics

### *Pharmacokinetics of SOMATULINE® AUTOGEL® in Healthy Volunteers*

Descriptive pharmacokinetics of lanreotide after Autogel deep subcutaneous administration was studied in healthy volunteers after a single administration. Results from this study show that the lanreotide release profile approximates log-linear following deep sc administration (Figure 3).

Studies in healthy elderly subjects receiving the immediate-release formulation of lanreotide showed an 85% increase in half-life and a 65% increase in mean residence time (MRT) of lanreotide compared to healthy young volunteers. However, there was no change in either AUC or  $C_{max}$  of lanreotide in elderly subjects compared to healthy young subjects.

**Figure 3: Mean, overlaid, plasma concentration-time profiles of lanreotide (ng/mL) after deep sc administration of SOMATULINE® AUTOGEL® T<sub>1</sub>, T<sub>2</sub>, and T<sub>3</sub> (dose = 60, 90, and 120 mg, respectively)**



Standard pharmacokinetic parameters monitored in this study following deep sc administration of SOMATULINE® AUTOGEL® to healthy volunteers are summarized below.

**Table 11: Pharmacokinetic parameters following a single deep subcutaneous administration of SOMATULINE® AUTOGEL® 60, 90, and 120mg to healthy volunteers**

Parameter	60mg (N=13)			90mg (N=13)			120mg (N=12)		
	Mean	SD	CV%	Mean	SD	CV%	Mean	SD	CV%
$C_{max}$ (ng/mL)	4.246	1.934	45.55	8.391	4.915	58.57	6.785	3.641	53.66
AUC <sub>t</sub> (ng/mL/h)	1634.61	435.19	26.62	2453.78	816.66	33.28	2984.81	1024.70	34.33

AUC <sub>∞</sub> (ng/mL/h)	1904.98	564.09	29.61	2984.35	1214.04	40.68	3552.26	947.33	26.67
t <sub>1/2</sub> (h)	664	455	68.52	860	431	50.12	816	334	40.93
t <sub>max</sub> (h)*	8 (4 to 336)	--	--	12 (4 to 336)	--	--	7 (2 to 48)	--	--
t <sub>lag</sub> (h)	<1.0	0.0	--	<1.0	0.0	--	<1.0	0.0	--
MRT (h)	940.62	462.83	49.20	1009.87	568.17	56.26	1102.13	469.61	42.61
MAT (h)	939.78	463.00	49.27	1009.11	568.28	56.31	1101.29	469.49	42.63
F (%)	83.25	34.56	41.51	78.14	25.87	33.11	80.87	24.18	29.90

\* = median and range in parenthesis

Both AUC<sub>t</sub> and AUC<sub>∞</sub> increased with the dose; C<sub>max</sub> increased from 60 to 90mg but at 120mg an intermediate value was obtained. The high inter-subject variability observed for this parameter could explain why a dose relationship was not observed for C<sub>max</sub>. Some variability was also observed in t<sub>max</sub> ranging between 2 and 48 hours, except in two volunteers who showed an unexpected value of 336 h. No important differences were observed in the median values obtained for these parameters (7 to 12 hours). The other parameters t<sub>1/2</sub>, t<sub>lag</sub>, MRT (Mean Residence Time), MAT (Mean Absorption Time) and F% showed similar values in the three dose groups. Mean t<sub>1/2</sub> ranged from 664 to 860 hours (28 to 36 days) and bioavailability ranged from 78% to 83%.

### ***Pharmacokinetics of SOMATULINE® AUTOGEL® in Patients with Acromegaly***

The primary pharmacokinetic results for SOMATULINE® AUTOGEL® are derived from a randomized parallel-group, double-blind, single-center study that evaluated the pharmacokinetic profile of SOMATULINE® AUTOGEL® administered at fixed doses of 60, 90 and 120mg four times every 28 days in 18 patients with active acromegaly.

Following a single dose, the pharmacokinetics of SOMATULINE® AUTOGEL® were dose-independent in the dose range 60 to 120mg. Dose proportionality was observed in the pharmacokinetic parameters C<sub>min, 1</sub>, C<sub>max</sub>, and AUC<sub>τ</sub> as shown in the table below.

**Table 12: Comparative Mean (± SD) Pharmacokinetic Parameters Following a First Single Dose of SOMATULINE® AUTOGEL® of 60, 90, and 120mg to Patients with Acromegaly**

Parameter (units)	60mg			90mg			120mg			p
	Mean	SD	N	Mean	SD	N	Mean	SD	N	
T <sub>max</sub> <sup>(1)</sup> (d)	0.25 (0.17-0.98)		6	0.25 (0.25-1.00)		5	0.98 (0.24-0.99)		5	0.433
C <sub>max</sub> (ng.mL <sup>-1</sup> )	1.650	0.623	6	3.543	2.546	5	3.053	0.932	5	0.694 <sup>(2)</sup>
C <sub>min</sub> (ng.mL <sup>-1</sup> )	0.725	0.191	6	0.973	0.199	5	1.406	0.306	6	0.699 <sup>(2)</sup>
AUC <sub>t</sub> (ng.mL <sup>-1</sup> d)	22.27	6.42	6	37.29	14.23	5	48.49	15.36	6	0.864 <sup>(2)</sup>

<sup>(1)</sup> For this parameter, the median and range values were used,

<sup>(2)</sup> p value corresponding to pharmacokinetic parameters normalized by dose

SOMATULINE<sup>®</sup> AUTOGEL<sup>®</sup> exhibited linear pharmacokinetics after repeated doses over the range of 60 to 120 mg administered once every 28 days (Table 12). Pharmacokinetic parameters  $C_{min,ss}$ ,  $C_{max,ss}$  and AUC increased in a dose-dependent linear manner. During the dosing interval, average steady state concentrations ( $C_{avg}$ ) of 2.457, 3.040 and 4.523 ng·mL<sup>-1</sup> were observed for the 60, 90 and 120mg dose levels, respectively.

**Table 13: Comparative Mean (± SD) Steady-State Pharmacokinetic Parameters Following Four Doses of SOMATULINE<sup>®</sup> AUTOGEL<sup>®</sup> 60, 90, 120 mg to Patients with Acromegaly**

Parameter (units)	60mg			90mg			120mg			p
	Mean	SD	N	Mean	SD	N	Mean	SD	N	
$T_{max,ss}$ <sup>(1)</sup> (d)	84.62 (84.17-85.99)		4	84.29 (84.17-85.99)		6	84.66 (84.33-85.97)		6	0.615 <sup>(2)</sup>
$C_{max,ss}$ (ng·mL <sup>-1</sup> )	3.821	0.509	4	5.694	1.672	6	3.053	0.932	6	0.974 <sup>(2)</sup>
$C_{min,ss}$ (ng·mL <sup>-1</sup> )	1.822	0.304	4	2.511	0.882	6	3.762	1.012	6	0.721 <sup>(2)</sup>
$AUC_t$ (ng·mL <sup>-1</sup> ·d)	68.79	8.53	4	85.11	17.10	6	4.523	0.988	6	0.279 <sup>(2)</sup>
$C_{avg}$ (ng·mL <sup>-1</sup> )	2.457	0.305	4	3.040	0.611	6	4.523	0.988	6	0.289 <sup>(2)</sup>

<sup>(1)</sup> For this parameter, the median and range values were used

<sup>(2)</sup> p value corresponding to pharmacokinetic parameters normalized by dose

Peak-trough fluctuation during the dosing interval was dose-independent in the dose range 60 to 120mg, with values of 81%, 108% and 86% for the 60, 90 and 120mg doses, respectively.

Four consecutive SOMATULINE<sup>®</sup> AUTOGEL<sup>®</sup> administrations produced a slight accumulation independent of the dose level, with a mean accumulation index of approximately 2.7. This accumulation result is not unexpected considering the long half-life of SOMATULINE<sup>®</sup> AUTOGEL<sup>®</sup>.

Following a single dose of SOMATULINE<sup>®</sup> AUTOGEL<sup>®</sup> 60, 90 and 120mg in Study 717,  $C_{min}$  increased with lanreotide dose. The minimum serum levels after at least four consecutive lanreotide administrations at the same dose (steady-state) also increased with dose. Although the increase in  $C_{min,ss}$  was slightly less than proportional to the dose for comparison of the 120mg and the 60mg doses in this study, no statistically significant differences by dose could be demonstrated when normalized by dose ( $C_{min,ss}/D$ ). These results indicate that SOMATULINE<sup>®</sup> AUTOGEL<sup>®</sup> exhibited linear pharmacokinetics in acromegalic patients over the range of 60 to 120 mg after four consecutive doses of SOMATULINE<sup>®</sup> AUTOGEL<sup>®</sup> once every 28 days. Moderate accumulation of lanreotide in the body was also observed during this study at all dose levels, with mean accumulation indices ( $R_{ac}$ ) of 2.6, 3.2 and 2.8 for the 60, 90 and 120mg doses, respectively.

The mean  $C_{max}$  values following initial dosing with SOMATULINE® AUTOGEL® were 2- to 4-fold higher than mean minimum serum levels after first Autogel administration ( $C_{min1}$ ), indicating that no initial burst effect is produced with this formulation for the three dose levels tested (60, 90, and 120mg). Consistent observations were made after multiple deep s.c. injections.

Pharmacokinetic data from studies evaluating the use of extended dosing intervals of SOMATULINE® AUTOGEL® 120mg every 6 or 8 weeks, demonstrated mean steady state  $C_{min}$  values between 1.6 and 2.3 ng/mL for the 8 and 6-week treatment intervals, respectively. The median minimum effective serum concentration of lanreotide required to reduce GH levels to  $\leq$  2.5ng/mL ranged from 0,95 to 1.13 ng/mL.

Studies evaluating the use of extended dosing intervals of SOMATULINE® AUTOGEL® 120mg every 6 or 8 weeks were not conducted in patients with moderate or severe hepatic or renal impairment. There are no pharmacokinetic data available regarding the use of SOMATULINE® AUTOGEL® 120 mg every 6 or 8 weeks in patients with moderate or severe hepatic or renal impairment.

***Pharmacokinetics of SOMATULINE® AUTOGEL® in Patients with Enteropancreatic NETs***

Individual PK parameters (post hoc Empirical Bayes Estimates) were obtained from a population PK model including 290 NETs patients. Descriptive statistics on individual PK parameter estimates are shown in Table 14.

**Table 14: Summary Statistics of Lanreotide Pool PK Model Parameters**

	<b>CL/F (L/day) [a]</b>	<b>V/F (L)</b>	<b>K<sub>A</sub> (day<sup>-1</sup>)</b>	<b>t<sub>1/2</sub>K<sub>A</sub> (days)</b>
Somatuline Autogel 120mg (N=298)				
Mean (SD)	519 (129)	26.3 (30.2)	0.0174 (0.00900)	49.8 (28.0)
Geometric mean	503	20.7	0.0156	44.4
Median	504	18.3	0.0157	44.3
5 <sup>th</sup> and 95 <sup>th</sup> percentiles	327-743	13.1-85.9	0.00750-0.0358	19.3-93.0
CL/F = apparent total plasma clearance; V/F = apparent volume of distribution; K <sub>A</sub> = constant of absorption; t <sub>1/2</sub> K <sub>A</sub> = absorption half life				
a Only 290 subjects provided at least one concentration and were included in the PK model building. However, the PK parameters were simulated for the whole population (N=298)				

In addition, SOMATULINE® AUTOGEL® 120 mg exposure parameters after a single dose and at steady state were simulated from the model. Summary statistics are presented for the single dose in Table 15 and for steady state in Table 16.

**Table 15: Summary Statistics of Derived SOMATULINE® AUTOGEL® 120mg Exposure Parameters After a Single dose**

	AUC <sub>0-28</sub> (ng*day/mL)	C <sub>max</sub> (ng/mL)	C <sub>min</sub> (ng/mL)	C <sub>avg</sub> (ng/mL)
Mean (SD)	88.6 (40.1)	7.49 (7.58)	2.40 (0.930)	3.44 (1.57)
Geometric Mean	80.1	5.73	2.20	3.11
Median	83.8	5.39	2.38	3.24
5 <sup>th</sup> and 95 <sup>th</sup> percentiles	38.5 to 162	2.17 to 20.6	1.14 to 4.05	1.48 to 6.33

AUC= Area under the curve over the dosing interval (4 weeks); C<sub>max</sub> = maximum concentration; C<sub>min</sub> = concentration at the end of a dosing interval; C<sub>avg</sub> = average concentration over the dosing interval (4 weeks); SD = standard deviation

**Table 16: Summary Statistics of Derived SOMATULINE® AUTOGEL® 120mg Exposure Parameters at Steady State**

	AUC <sub>0-28</sub> (ng*day/mL)	C <sub>max</sub> (ng/mL)	C <sub>min</sub> (ng/mL)	C <sub>avg</sub> (ng/mL)
Mean (SD)	239 (64.8)	13.9 (7.44)	6.56 (1.99)	8.64 (2.36)
Geometric Mean	232	12.8	6.23	8.35
Median	231	11.9	6.49	8.41
5 <sup>th</sup> and 95 <sup>th</sup> percentiles	158-358	7.69-25.5	3.53-9.99	5.49-12.9

AUC= Area under the curve over the dosing interval (4 weeks); C<sub>max</sub> = maximum concentration; C<sub>min</sub> = concentration at the end of a dosing interval; C<sub>avg</sub> = average concentration over the dosing interval (4 weeks); SD = standard deviation

Rapid initial release was seen with mean C<sub>max</sub> values of 7.49 ± 7.58 ng/mL reached within the first day after a single injection. Steady-state concentrations were reached after 4 to 5 injections of SOMATULINE® AUTOGEL® 120mg every 4 weeks and were sustained up to the last assessment (up to 96 weeks after the first injection). At steady state, the mean C<sub>max</sub> values were 13.9 ± 7.44 ng/mL and the mean trough serum levels were 6.56 ± 1.99 ng/mL. The mean apparent terminal half-life was 49.8 ± 28.0 days.

### Excretion and Metabolism

Two studies examined the excretion of lanreotide. When lanreotide was given as a single sc dose of 3 mg, less than 1% of the administered dose was recovered in urine, and renal clearance was <1% of total plasma clearance. When lanreotide was given by sc infusion, the fraction of lanreotide excreted in the urine at steady state was 1% to 5% for a dose of 0.75 mg/day. Data for fecal excretion were collected in this study and less than 0.5% of the administered dose was recovered over a 24-hour period at steady state.

Therefore, urinary and fecal excretion represents only a small fraction of the total dose administered. This suggests that lanreotide is probably metabolized extensively in the gastrointestinal tract after biliary excretion.

### ***Intrinsic Factor Pharmacokinetic Studies***

Pharmacokinetic studies have been conducted with lanreotide in patients with chronic renal failure, hepatic failure and in elderly subjects.

**Table 17: Summary of Lanreotide's Pharmacokinetic Parameters\* in Special Populations**

	<b>C<sub>max</sub> (ng/mL)</b>	<b>t<sub>½</sub> (h)</b>	<b>AUC<sub>0-inf</sub> (ng/mL.h)</b>	<b>Clearance (l/h.kg)</b>	<b>Volume of distribution (l/kg)</b>
<i>Geriatric Patients</i>					
<b>Single dose mean</b> Study E-92-52030-012	48.75	1.74	29.17	0.269	0.200
<i>Hepatic Insufficiency</i>					
<b>Single dose mean</b>					
<b>Mild to Moderate</b> Study E-92-52030-013	28.74	1.66	20.02	0.362	0.322
<b>Moderate to Severe</b> Study E-38-52030-701	34.394	2.998	30.090	0.237	0.349
<i>Severe Chronic Renal Insufficiency</i>					
<b>Single dose mean</b> Study E-92-52030-011	307.45	2.39	62.95	0.138	0.110

\*Lanreotide was administered intravenously as the immediate release formulation

Differences were observed in the pharmacokinetics of lanreotide in renal, hepatic, and geriatric populations. No gender differences were found in PK parameters.

### ***Extrinsic Factor Pharmacokinetic Studies***

The potential for interference between lidocaine and lanreotide was studied. The binding of lidocaine in serum varied from 78.84% to 68.28% when the concentration increased from 4 to 20 µM. Binding remained unchanged in the presence of 400 nM of lanreotide. This confirms that lanreotide, given its moderate total binding, its average affinity for acid alpha-1 glycoprotein (65000 M<sup>-1</sup>), and its very low therapeutic serum concentration (-100 nM), cannot displace other drugs bound to this protein.

The potential for drug-drug interactions of lanreotide between SOMATULINE® AUTOGEL® and cyclosporin and vitamin K has been evaluated. Lanreotide decreased the bioavailability of oral cyclosporin by approximately 20%. No significant interaction with vitamin K was observed.

Literature comparisons of lanreotide with Sandostatin and Somatostatin UCB show that the principal pharmacodynamics interaction that may occur is the inhibition of glucagon secretion which may lead to the onset of hypoglycemia in treated diabetic patients, notably insulin-dependent patients. Thus, the insulin requirements in insulin-dependent diabetic patients may be reduced.



## MICROBIOLOGY

Not applicable.

## TOXICOLOGY

An immediate-release formulation (IRF) of lanreotide, administered either by sc injection or as an iv infusion was used for most of the toxicology studies. This allowed considerably higher doses to be achieved than would have been possible with the Autogel formulation.

### Single Dose Toxicity Studies

**Table 18: Summary of lanreotide single dose toxicity studies**

Species	Route	Dose	No effect dose (mg/kg)	Minimal effect dose (mg/kg)	LD50 (mg/kg)
Mouse	i.v.	0.8, 30, 100, 120, 135, 150, 180mg/kg	<30	30	120-135
Rat	i.v.	3, 6, 24, 48, 60, 75mg/kg	3	>6	>48
Mouse	s.c.	0.8, 600, 900, 1200mg/kg	<600	600	>1200
Rat	s.c.	0.8, 1500mg/kg	<1500	1500	>1500

The results of the single dose i.v. and s.c. studies indicated that both rodent species were able to tolerate large doses of lanreotide. There was no evidence of organ specific toxicity.

**Table 19: Summary of lanreotide repeat dose toxicity studies**

Species	Route	Duration	Doses (mg/kg/day)
Mouse	s.c.	5 days	0.8
Mouse	s.c.	13 weeks	0, 10, 30, 60
Mouse	s.c.	13/20 weeks	0, 0.5, 5*, 1 od 0.1*, 0.5 bid (*0.1 changed to 5 Weeks 8-20)
Rat	s.c.	6 weeks	0, 0.004, 0.04, 0.2
Rat	s.c.	13 weeks	0, 0.5, 1 od 0.1, 0.5 bid
Rat	s.c.	26 weeks	0, 0.2, 1.0, 5.0 (3.0, 2.0)
Rat	i.v. infusion	14 days	0, 1, 5, 20
Dog	s.c.	6 weeks	0, 0.004, 0.04, 0.2
Dog	i.v. infusion (dose finding)	14 days	2.5, 5.0, 10 (6 days) 20, 25
Dog	i.v. infusion	45 days	0, 0.4, 4.0, 10
Dog	i.m.	26 weeks	1.00-1.62, 3.35-4.98, 6.26-9.95 mg/kg once every 2 weeks

The toxicological effects associated with repeated subcutaneous, intramuscular and intravenous

administrations were assessed in mice and/or rats and dogs (see Table above). Chronic toxicity was assessed in the rat and in the dog. The results of these studies revealed no evidence of target organ toxicity. Inhibition of growth rates observed at high doses was considered to be secondary to lanreotide's recognized pharmacologic effect, inhibition of growth hormone secretion. Similarly, lanreotide-associated reductions in serum concentrations of some hormones were considered to be extensions of the pharmacologic effect. Continuous infusion of lanreotide to dogs for up to 45 days was associated with dose-related testicular immaturity in males. Control animals also had immature testicles but the degree of immaturity appeared to increase in a dose-related fashion and was consistent with the general growth retardation of lanreotide treated animals.

With the exception of dose-related irritation at the site of injection, lanreotide was well tolerated by all test species and the results indicate little, if any, potential for chronic administration of the drug in humans to produce target organ toxicity.

### Chronic Toxicity Studies

**Table 20: Summary of lanreotide chronic toxicity studies**

Species	Route	Duration	Doses (mg/kg/day)
Rat	s.c.	24 months	0, 0.008, 0.040, 0.120
Dog	s.c.	24 months	0, 0.008, 0.040, 0.120

The chronic toxicity of subcutaneously administered lanreotide was assessed in a 24 months study in rats. The results of this study were similar to those of shorter-term repeated dose studies in that there was no evidence of systemic, organ specific toxicity. Further, there was no evidence that lanreotide influenced the incidence or rate of onset of spontaneously occurring neoplasms in this strain of rats.

Chronic toxicity (24 months) was also assessed in dogs. The results of this study corroborated the absence of significant systemic toxicity observed in dogs after shorter-term repeated dose studies.

### Genotoxicity

**Table 21: Summary of *In Vivo* and *In Vitro* Mutagenicity Studies**

Test	Lanreotide Concentration	Organism/Cell Source	Metabolic Activation S9
<b>Non-mammalian <i>in vitro</i> assays</b>			
AMES test	1.6 to 5000 mcg/plate	TA 1535	(+/-)
		TA 100	(+/-)
		TA 1537	(+/-)
		TA 98	(+/-)

		WP2 uvrA	(+/-)
<b>Mammalian cell <i>in vitro</i> assays</b>			
Mouse lymphoma assay	100-1200 mcg/ml	Mouse lymphoma cells	(+/-)
Chromosomal aberration assay	393.7 – 2000 mcg/ml	Human lymphocytes	(+/-)
<b><i>In vivo / in vitro</i> Mutation frequency and DNA synthesis and repair assays</b>			
Induction of gene mutations in liver and bone marrow tissue	120 or 180 mg/kg/day subcutaneous	Male CD <sub>2</sub> -lacZ80/HazfBRstrain mice	NA
<b>Mammalian cell <i>in vivo</i> assays (PO)</b>			
Micronucleus test	6.25, 12.5, 25 mg/k/day intravenous	Male and female Swiss Ico:OF1 (IOPS Caw) mice	NA

The standard battery of genotoxicity tests was performed. In this set of studies, no positive results were obtained.

### **Carcinogenicity**

A two-year mouse carcinogenicity study was conducted wherein males and females were administered lanreotide once daily by subcutaneous injection at 0.5, 1.5, 5, 10 and 30 mg/kg/day. Reduced survival was observed at 30 mg/kg/day in males and females and was related to the presence of masses at subcutaneous injection sites (increased incidence of fibrosarcomas and malignant fibrous histiocytomas). No systemic neoplastic changes were observed.

A two-year rat carcinogenicity study was conducted wherein males and females were administered lanreotide once daily by subcutaneous injection at 0.1, 0.2, and 0.5 mg/kg/day. Survival rate was comparable in male treated groups compared to male control groups. In females, survival rate tended to be higher at all dose levels. No systemic neoplastic changes were observed. At injection sites of male and female rats treated with 0.5 mg/kg/day lanreotide, an increased incidence of fibrosarcomas and malignant fibrous histiocytomas was observed.

The increased incidence of subcutaneous tumours at injection sites is likely due to the increased dose frequency in animals (daily). Considering that monthly dosing is recommended in human, these findings may not be clinically relevant. Exposure multiples (ratio of animal AUC to human AUC) were not calculated as systemic tumours were not observed.

### **Reproductive Toxicity**

The high dose somatostatinergic effects of lanreotide on the secretion of pituitary hormones can be expected to cause perturbations of reproduction. The effects of lanreotide on mating behaviour and reproductive performance were assessed in male and female rats by administering the drug by the s.c. and/or i.m. routes.

Although administered at doses sufficiently high to reduce growth rates of both males and females of the F<sub>0</sub> generation neither mating behaviour nor reproductive performance were adversely affected. The behavioural and reproductive characteristics of the F<sub>1</sub> and F<sub>2</sub> generations were similarly unaffected by administration of lanreotide to the parental generations.

Teratological potential was assessed by daily administering s.c. doses of lanreotide (0, 100, 450, or 2000 mcg/kg) to pregnant rats (from gestation day 6 to 15) and rabbits (from gestation day 6 to 18). The doses were selected on the basis of preliminary dose range finding studies, at doses up to and including 5000 mcg/kg/day, which are included within the documentation. Female rats administered the 2000 mcg/kg dose exhibited decreased weight gains but there was no evidence of either foetal toxicity or teratological anomalies. In rabbits, all dosed groups had reduced body weight gains and there was evidence of foetal toxicity (increased post implant loss in the 450 and 2000 mcg/kg groups) but no evidence of either soft tissue or skeletal anomalies.

### Local Tolerance

Specific tolerance studies with the SOMATULINE® AUTOGEL® formulation have been conducted, and are summarized below.

**Table 22: Summary of lanreotide local tolerance studies**

Species/Strain	Method of Administration	Doses (mg/kg)
Rabbit/NZW	Single i.m.	60 mg per animal
Rabbit /NZW	Repeated i.m.	10 mg per animal /4 weeks
Rabbit/NZW	Single s.c.	60 mg per animal
Rabbit/NZW, Monkey / Cynomolgus, Minipig/ Gottingen	Single s.c.	60 mg per animal
Rabbit	Repeated s.c.	10 mg per animal / 4 weeks

Local tolerance testing involved following animals for up to 150 days after s.c. or i.m. injection, in single and multiple dose studies. Local tolerance was adequate to support the prolonged intermittent use of SOMATULINE® AUTOGEL® in patients. Findings can be summarized as follows. The local tolerance on i.m. and s.c. injection was acceptable. Local tolerance studies of the Autogel formulation proposed for marketing showed a locally restricted response with development of a fibrous capsule at the injection site. The response was not severe and is likely to be similar to the effects of injecting other biocompatible materials. No general adverse reactions were observed and there was no difference in local tolerance after multiple doses compared to single injections.

### Immunotoxicity

Provision was made to assess the potential to adversely affect lymphocytes, macrophages and natural killer cells during the course of a 45-day continuous i.v. infusion toxicity study in beagle dogs. No effects were found at doses of 0.4, 4 or 10 mg/kg to indicate that lanreotide has any potential to modify the selected immunotoxicity end-points.

Lanreotide is a small peptide whose molecular weight is below the approximate 10000 minimum for antigenicity independently of any haptenic function. Neither modifications of the hematology parameters nor lesions of the lymphoid organs, which may be indicative of immunostimulation, were observed in treated rats and dogs.

Blood samples obtained from rats after 26 weeks and 24 months of daily s.c. administration of lanreotide at doses of 0, 8, 40 and 120 mcg/kg/day tested negative for anti-lanreotide antibodies. Thus, no evidence was obtained in these studies to conclude that lanreotide has any immunogenic potential when repeatedly administered to rats for prolonged periods.

## REFERENCES

Phase II, multi-centre, randomised, double-blind study, in acromegalic patients evaluating the efficacy and safety of a single deep subcutaneous administration of lanreotide autogel (60, 90 or 120 mg) versus placebo, followed by a single-blind fixed dose phase evaluating the pharmacokinetic, pharmacodynamic, efficacy and safety profile of multiple deep subcutaneous administrations of lanreotide autogel (60, 90 & 120 mg) ending in open label dose titration phase. Study E28.52030.717 Data on file. Beaufour Ipsen Pharma 2004.

Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumours, Caplin M, et. al., N Engl J Med 371;3, July 17, 2014.

## PART III: CONSUMER INFORMATION

### PrSOMATULINE® AUTOGEL®

lanreotide injection

60, 90, 120 mg lanreotide (as acetate)/unit (syringe)

This leaflet is part III of a three-part “Product Monograph” published when SOMATULINE® AUTOGEL® was approved for sale in Canada and is designed specifically for Consumers. This leaflet is a summary and will not tell you everything about SOMATULINE® AUTOGEL®. Contact your doctor or pharmacist if you have any questions about the drug.

### ABOUT THIS MEDICATION

#### What the medication is used for:

SOMATULINE® AUTOGEL® is recommended for:

- The treatment of acromegaly;
- The treatment of adults with a type of cancer known as enteropancreatic neuroendocrine tumours from the intestinal tract or the pancreas that cannot be removed by surgery or has spread.
- The treatment of adults with carcinoid syndrome to reduce the need for a type of rescue medicine.

#### What is Acromegaly?

Acromegaly is a rare and debilitating disease. It happens when the pituitary gland (a pea-sized gland in the brain) produces too much growth hormone. This can cause changes in the bones of the face and in the levels of other specific hormones. If left untreated, acromegaly can lead to other medical problems.

#### What are Enteropancreatic Neuroendocrine Tumours?

Enteropancreatic neuroendocrine tumours are growths that have developed from endocrine cells in the gastrointestinal tract (the stomach, intestines and appendix) or the pancreas.

Some symptoms come about because some neuroendocrine tumours produce and secrete small proteins in excess – overloading the system.

#### What is Carcinoid Syndrome?

Carcinoid syndrome occurs when rare cancerous neuroendocrine tumours called carcinoid tumours release proteins into your bloodstream, causing signs and symptoms, including diarrhea and flushing. Carcinoid tumours generally occur in the esophagus, stomach, intestines, appendix, and lungs.

Diarrhea can cause dehydration, it is therefore very important to control it and replace the loss of water and electrolytes as quickly as possible.

#### What it does:

SOMATULINE® AUTOGEL® is a long-acting formulation of lanreotide that lasts for several weeks. Lanreotide is similar to the naturally occurring hormone somatostatin. Lanreotide lowers the levels of hormones in the body such as GH (growth hormone) and IGF-1 (insulin-like growth factor-1) and blocks

the release of hormones and secretions in the stomach and intestines. Additionally, it has an effect on some neuroendocrine tumours by delaying growth and helping to reduce the symptoms of too much serotonin such as diarrhea and flushing.

#### When it should not be used:

SOMATULINE® AUTOGEL® should not be used if you:

- have previously been allergic to lanreotide or any other drug like somatostatin;
- have untreated gallstones

#### What the medicinal ingredient is:

lanreotide acetate

#### What the important non medicinal ingredients are:

The only excipients are water for injection and glacial acetic acid (for pH adjustment).

#### What dosage forms it comes in:

SOMATULINE® AUTOGEL® is packaged in a sterile, pre-filled syringe fitted with an automatic safety system, ready to be injected. It is available in three strengths of 60mg, 90mg and 120mg.

### WARNINGS AND PRECAUTIONS

#### Serious Warnings and Precautions

Treatment with SOMATULINE® AUTOGEL® may:

- cause loss of blood sugar control in diabetic patients
- cause gallstones
- affect (lower) the blood level of cyclosporine

BEFORE you use SOMATULINE® AUTOGEL® talk to your doctor or pharmacist if:

- you are diabetic
- you have or have had liver problems
- you have or have had kidney problems
- you have or have had heart problems
- you have or have had gall bladder problems
- you have thyroid problems
- you are pregnant, planning to become pregnant
- you are breast-feeding

SOMATULINE® AUTOGEL® is not recommended for patients under 18 years of age.

**Driving and using machines:** Before you perform tasks which may require special attention, wait until you know how you respond to SOMATULINE® AUTOGEL®. Dizziness and headaches can occur after the first dose and when the dose is increased.


### INTERACTIONS WITH THIS MEDICATION

Before and during treatment with SOMATULINE® AUTOGEL® tell your doctor or pharmacist if you are taking or have recently taken any other medicines. This

includes medicines that you can buy without prescription, and herbal products.

Drugs that may interact with SOMATULINE<sup>®</sup> AUTOGEL<sup>®</sup> include:

- cyclosporine, a drug that blocks the activity of the immune system
- bromocriptine, a drug that blocks prolactin (a hormone released by the pituitary gland)
- drugs that slow heart rate



## PROPER USE OF THIS MEDICATION

### Usual Adult Dose:

If you have acromegaly, the recommended starting dose is an injection of SOMATULINE<sup>®</sup> AUTOGEL<sup>®</sup> 90 mg. You will normally be given one injection every 28 days. Your doctor may change the dose or the length of time between your injections, depending on how your symptoms and hormones are responding to the product. Your doctor will tell you how long you need to receive SOMATULINE<sup>®</sup> AUTOGEL<sup>®</sup>.

If you have a neuroendocrine tumour in the intestine or pancreas or you have carcinoid syndrome, you will receive a SOMATULINE<sup>®</sup> AUTOGEL<sup>®</sup> 120 mg injection every 4 weeks for as long as your doctor recommends.

SOMATULINE<sup>®</sup> AUTOGEL<sup>®</sup> is given as a deep subcutaneous (under the skin) injection by a healthcare professional or a properly trained person. You may give yourself an injection, in the thigh region only, if you have been properly trained and are able to follow the Instructions for Administration of SOMATULINE<sup>®</sup> AUTOGEL<sup>®</sup>.


### INSTRUCTIONS FOR ADMINISTRATION OF SOMATULINE<sup>®</sup> AUTOGEL<sup>®</sup> FOLLOW THESE INSTRUCTIONS CAREFULLY.

1. Remove SOMATULINE<sup>®</sup> AUTOGEL<sup>®</sup> from the fridge 30 minutes prior to administration. Keep pouch sealed until just prior to injection.
2. Before opening the pouch, check that it is intact and that the medication has not expired. The expiration date is printed on the outer carton and the pouch. **DO NOT USE IF THE MEDICATION HAS EXPIRED OR IF THE LAMINATED POUCH IS DAMAGED IN ANY WAY.**
3. Wash hands with soap and ensure there is a clean area for preparation.
4. Tear-open the pouch and take out the pre-filled syringe.

### 5. Select an injection site:


5a: The superior external quadrant of the buttock (for injection by healthcare professional (HCP) or someone else like a trained family member or friend), or

5b: The upper outer part of your thigh (if you will be injecting yourself).




6. Clean the injection site with a sterile gauze without rubbing the skin excessively.

7. Twist and pull off the plunger protector and discard it.





8. Remove the needle cap and discard it.




9. Hold the skin around the injection site flat using your thumb and index finger. Do not pinch, fold, or press on the skin at the injection site. Rapidly insert the needle to its full length (deep subcutaneous injection), perpendicular (90°) to the skin







10. Slowly inject the drug. **Typically 20 seconds are needed.** Inject the full dose until the plunger cannot be depressed any further. At this point, you will hear a “click”. Maintain pressure on the plunger with your thumb to avoid activation of the automatic safety system.



11. Without releasing the pressure on the plunger, withdraw the needle from the injection site.



12. Then release pressure on the plunger. The needle will automatically retract into the needle guard where it will be locked permanently.



13. Apply gentle pressure to the injection site with a dry cotton ball or sterile gauze to prevent any bleeding. Do not rub or massage the injection site after administration.

14. Properly dispose of the used syringe.

#### Overdose:

In case of drug overdose, contact your doctor or Poison Control Centre or go to the emergency room of the hospital near you.

#### Missed Dose:

As soon as you realize that you have missed an injection, contact your doctor. They will give you advice about the timing of your next injection. Do NOT give yourself extra injections to make up for the one that you have forgotten.

### SIDE EFFECTS AND WHAT TO DO ABOUT THEM

These are not all the possible side effects you may feel when taking SOMATULINE® AUTOGEL®. If you experience any side effects not listed here, contact your doctor.

- flatulence (passing gas)
- weight loss
- loss of appetite
- indigestion
- nausea
- constipation
- fatty stools (stools may be bulky and appear pale and oily)
- swollen tummy
- confusion
- dizziness
- eye redness
- ringing in the ears
- tiredness or decreased energy
- hair loss
- muscle pains or spasms
- joint, bone, or mouth pain
- weakness, numbness, tingling or pain in the hands or feet
- swelling in the arms or legs
- pain during menstruation
- feeling hot with reddening of the skin
- excessive sweating
- night sweats
- hard swelling of the injection site, and rarely a persistent hard swelling

SOMATULINE® AUTOGEL® can cause abnormal blood test results. Your doctor will decide when to perform blood tests and other tests like gall bladder ultrasound. Your doctor will interpret the results.

## SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM

Symptom / effect		Talk with your doctor or pharmacist	
		Only if severe	In all cases
Very common	Abdominal pain	yes	
	Diarrhea or loose stools	yes	
	Formation of gallstones in the gall bladder: sudden severe pain in the upper right abdomen which may last for hours, maybe accompanied by nausea and vomiting		yes
	Headache	yes	
	Vomiting	yes	
	Anemia: fatigue, loss of energy, weakness, shortness of breath	yes	
Common	Injection site reaction: site of injection may be tender, warm, red or itchy	yes	
	Decreased heart rate (bradycardia)		yes
	High blood pressure: headaches, vision disorders, nausea and vomiting		yes
	Underactive thyroid gland (hypothyroidism) causing changes in heart rate, appetite or weight, tiredness, feeling cold or swelling at the front of the neck		yes
	Pancreatitis (inflammation of the pancreas): severe abdominal pain which may spread out towards the back, nausea, vomiting, increased heart rate		yes
	Liver problems: yellowing of the skin or eyes, dark urine, abdominal pain, nausea, vomiting, loss of appetite, itching, bruising, weight loss		yes
	Diabetes, worsening of diabetes, or high blood sugar: unusual thirst, frequent urination, extreme fatigue or lack of energy, tingling or numbness in the hands or feet		yes
	Low blood sugar: dizziness, sweating, confusion, headache, blurred vision, fast heartbeat, mood changes		yes
Uncommon	Allergic skin reactions: rash, hives, itching, redness	yes	

Post-marketing	Severe allergic reactions: swollen face, lips, mouth or tongue, tightness in chest, shortness of breath or wheezing fainting, dizziness or feeling lightheaded due to a drop in blood pressure, flushing or redness of the skin, rash or hives		yes
	Injection site reaction: site of injection may be swollen and / or painful with a build-up of pus under the skin	yes	

*This is not a complete list of side effects. For any unexpected effects while taking SOMATULINE® AUTOGEL®, contact your doctor or pharmacist.*

## HOW TO STORE IT

Store SOMATULINE® AUTOGEL® at 2°C-8°C in a refrigerator in its original package. Do not freeze. Keep out of the reach and sight of children. Do not use after the expiry date shown on the labels and box.

## Reporting Suspected Side Effects

You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:

- Report online at [www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html](http://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html)
- Call toll-free at 1-866-234-2345
- Complete a Canada Vigilance Reporting Form and:
  - Fax toll-free to 1-866-678-6789, or
  - Mail to:
 

Canada Vigilance Program  
Health Canada  
Postal Locator 1908C  
Ottawa, Ontario  
K1A 0K9

Postage paid labels, Canada Vigilance Reporting Form and the adverse reaction reporting guidelines are available on the MedEffect™ Canada website at [www.healthcanada.gc.ca/medeffect](http://www.healthcanada.gc.ca/medeffect).

*NOTE: Should you require information related to the management of the side effects, contact your health professional. The Canada Vigilance Program does not provide medical advice.*

## MORE INFORMATION

This document plus the full product monograph, prepared for health professionals can be found at:

Ipsen Biopharmaceuticals Canada Inc. at 5060 Spectrum Way  
Mississauga ON L4W 5N5. [www.ipsen.ca](http://www.ipsen.ca)  
or by calling 1-855-215-2288.

This leaflet was prepared by Ipsen Biopharm Ltd.

©2018 Ipsen Biopharmaceuticals. All rights reserved.  
SOMATULINE AUTOGEL is a registered trademark of  
IPSEN BIOPHARM LTD.

Last revised: August 31, 2018